Xa阻害薬のすべて

出版社： 先端医学社
著者：
発行日： 2007-06-25
分野： 臨床医学：内科  >  血管
ISBN： 9784884073978
電子書籍版： 2007-06-25 （第1版第1刷）
書籍・雑誌
≪全国送料無料でお届け≫
取寄せ目安：8～14営業日

5,170 円(税込)

購入する
電子書籍
章別単位で購入
ブラウザ、アプリ閲覧

2,585 円(税込)

購入する

商品紹介

静脈血栓塞栓症予防薬である?a阻害薬を正しく理解し、活用するための必読書。近年わが国でも静脈血栓塞栓症（VTE）予防の必要性が叫ばれ、2004年には予防ガイドラインも作成されました。本書はVTEの予防薬となるXa阻害薬を安全に使用するための指南書です。Xa因子の機能、疾患との関連などの分子機序から、Xa阻害薬の薬理作用、臨床エビデンス、副作用、開発中の薬剤までを幅広く解説。VTE発症が各科で問題となっている今、多くの医療スタッフ必読の一冊です。

目次

  • Xa阻害薬のすべて

    ―目次―

    Part 1　凝固カスケード：up-date
    　1．Xa因子の生成系（Xa因子の上流）
    　2．Xa因子の構造と活性化反応（Xa因子の下流）
    　3．Xa因子の細胞生理活性

    Part 2　Xa因子と疾患との関連
    　1．Xa因子から生体反応をみる
    　2．Xa因子と血栓―病的血栓の発症に果たすXa因子の役割―
    　3．Xa因子と炎症・DIC

    Part 3　Xa因子の制御機構

    Part 4　Xa阻害薬の薬理学的特徴をみる
    　1．抗凝固薬の歴史とXa阻害薬の開発目的を探る
    　2．Xa阻害薬の薬理学的プロフィールと臨床応用をみる
    　3．Xa阻害薬の炎症制御による臓器障害抑制を探る
    　4．Xa阻害薬を基礎薬理から考察する

    Part 5　血栓塞栓症の病態と抗凝固療法の現状を探る
    　1．血栓形成メカニズムと抗凝固療法を探る
    　2．静脈血栓塞栓症の現状と問題点を探る
    　3．内科領域における血栓塞栓症の発症機序と
    　　　抗凝固療法の現状をみる
    　4．外科領域における血栓塞栓症の発症機序と
    　　　抗凝固療法の現状をみる

    Part 6　臨床応用におけるXa阻害薬の位置づけを探る
    　1．血栓塞栓症に対する薬剤選択基準とわが国における
    　　　Xa阻害薬の位置づけを探る
    　2．海外におけるXa阻害薬の臨床評価と位置づけを探る
    　　　−EBMからの考察―
    　3．ガイドラインにおけるXa阻害薬の位置づけと
    　　　今後の可能性をみる
    　4．急性肺血栓塞栓症の治療における抗凝固療法の実際と
    　　　Xa阻害薬の位置づけを探る
    　5．ヘパリン起因性血小板減少症（HIT）の現況と
    　　　Xa阻害薬の位置づけを探る
    　6．入院患者におけるXa阻害薬の位置づけを探る

    Part 7　各科領域におけるXa阻害薬の臨床応用の可能性をみる
    　1．外科領域における静脈血栓塞栓症とXa阻害薬の有効性をみる
    　2．循環器領域におけるXa阻害薬の臨床評価をみる
    　3．整形外科領域におけるXa阻害薬の臨床応用をみる

    Part 8　Xa阻害薬の安全性と副作用をみる

    Part 9　Xa阻害薬の将来展望を探る
    　1．わが国の医療経済における血栓塞栓症治療と
    　　　Xa阻害薬の役割を探る
    　2．Xa阻害薬の今後の可能性を探る

この書籍の参考文献

参考文献のリンクは、リンク先の都合等により正しく表示されない場合がありますので、あらかじめご了承下さい。

本参考文献は電子書籍掲載内容を元にしております。

Part1 凝固カスケード : up-date

P.22 掲載の参考文献
1) 図説 血栓・止血・血管学-血栓症の制圧のために-, 一瀬白帝編著, 中外医学社, 東京, 2005
 
2) 三輪血液病学, 浅野茂隆ほか監修, 文光堂, 東京, 2006
 
3) 別冊・医学のあゆみ血液疾患state of arts ver.3, 坂田洋一ほか編, 医歯薬出版, 東京, 2005
 
4) Bach RR : Tissue factor encryption. Arterioscler Thromb Vasc Biol 26 : 456-461, 2006
PubMed
5) Monroe DM, Hoffman M : What does it take to make the perfect clot? Arterioscler Thromb Vasc Biol 26 : 41-48, 2006
PubMed
6) Szotowski B, Antoniak S, Poller W et al : Procoagu. lant soluble tissue factor is released from endothelial cells in response to inflammatory cytokines. Circ Res 96 : 1233-1239, 2005
 
7) Stampfuss JJ, Censarek P, Fischer JW et al : Rapid release of active tissue factor from human arterial smooth muscle cells under flow conditions. Arterioscler Thrormb Vasc Biol 26 : e34-e37, 2006
PubMed
8) Engelmann B : Initiation of coagulation by tissue factor carriers in blood. Blood Cells Mol Dis 36 : 188-190, 2006
PubMed
9) Bogdanov VY, Balasubramanian V, Hathcock J et al : Alternatively spliced human tissue factor : acircu. lating, soluble, thrombogenic protein. Nat Med 9 : 458-462, 2003
 
10) Renne T, Pozgajova M, Gruner S et al : Defective thrombus formation in mice lacking coagulation factor XII. J Exp Med 202 : 271-281, 2005
PubMed
11) Johne J, Blume C, Benz PM et al : Platelets promote coagulation factor XII-mediated proteolytic cascade systems in plasma. Biol Chem 387 : 173-178, 2006
PubMed
12) Kleinschnitz C, Stoll G, Bendszus M et al : Targeting coagulation factor XII provides protection from pathological thrombosis in cerebral ischemia without interfering with hemostasis. J Exp Med 203 : 513-518, 2006
PubMed
13) Colman RW : Are hemostasis and thrombosis two sides of the same coin? J Exp Med 203 : 493-495, 2006
 
14) Renne T, Nieswandt B, Gailani D : The intrinsic pathway of coagulation is essential for thrombus stability in mice. Blood Cells Mol Dis 36 : 148-151, 2006
PubMed
15) Furie B, Furie BC : Thrombus formation in vivo. J Clin Invest 115 : 3355-3362, 2005
PubMed
16) Weitz JI, Bates SM : New anticoagulants. J Thromb Haemost 3 : 1843-1853, 2005
PubMed
17) Nieman MT, Warnock M, Hasan AA et al : The preparation and characterization of novel peptide antagonists to thrombin and factor VIIa and activation of protease-activated receptor 1. J Pharmacol Exp Ther 311 : 492-501, 2004
PubMed
18) Kohrt JT, Filipski KJ, Cody WL et al : The discovery of fluoropyridine-based inhibitors of the factor VIIa/TF complex-part 2. Bioorg. Med Chem Lett 16 : 1060-1064, 2006
PubMed
19) Arnold CS, Parker C, Upshaw R et al : The antithrombotic and anti-inflammatory effects of BCX-3607, a small molecule tissue factor/factor VIIa inhibitor. Thromb Res 117 : 343-349, 2006
PubMed
20) Vijaykumar D, Sprengeler PA, Shaghafi M et al : Discovery of novel hydroxy pyrazole based factor IXa inhibitor. Bioorg Med Chem Lett 16 : 2796-2799, 2006
PubMed
21) 岡本貴行, 鈴木宏治 : 組織因子をめぐる最近の話題. Annual Review血液2006, 高久史麿ほか編, 中外医学社, 東京, 2006, pp.248-258
 
P.31 掲載の参考文献
1) 図説 血栓・止血・血管学-血栓症制圧のために-, 一瀬白帝編, 中外医学社, 東京, 2005
 
2) 森田隆司 : 血液凝固機構の新しい考え方. 日小血会誌17 : 49-57, 2003
 
3) Morita T : Use of snake venom inhibitors in studies of the function and tertiary structue of coagulation factors. Int J Hematol 79 : 123-129, 2004
 
4) riedrich R, Panizzi P, Fuentes-Prior P et al : Staphylocoagulase is a prototype for the mechanism of cofactor-induced zymogen activation. Nature 425 : 535-539, 2003
 
5) Bode W, Huber R : Induction of the bovine trypsinogen-trypsin transition by peptides sequentially similar to the N-terminus of trypsin. FEBS Lett 68 : 231-236, 1976
 
6) 山崎泰男, 森田隆司 : Staphylocoagulaseとプレトロンビン-2複合体のX線結晶構造解析から明らかになったセリンプロテアーゼ前駆体の活性化メカニズムの原型と共通原理-Streptokinaseとの相違点と共通性-. 血栓止血誌15 : 140-145, 2004
 
7) Mizuno H, Fujimoto Z, Atoda H et al : Crystal structure of an anticoagulant protein in complex with the Gla domain of factor X. Proc Natl Acad Sci USA 98 : 7230-7234, 2001
PubMed
8) Kamata K, Kawamoto H, Honma T et al : Structural basis for chemical inhibition of human blood coagulation factor Xa. Proc Natl. Acad Sci USA 95 : 6630-6635, 1998
PubMed
9) 山崎泰男, 森田隆司 : プロトロンビンの基礎と臨床. 図説 血栓・止血・血管学-血栓症制圧のために-, 一瀬白帝編, 中外医学社, 東京, 2005, pp.295-304
 
10) Rost S, Fregin A, Ivaskevicius V et al : Mutations in VKORCI cause warfarin resistance and multiple coagulation factor deficiency type 2. Nature 427 : 537-541, 2004
 
11) Li T, Chang CY, Jin DY et al : Identification of the gene for vitamin K epoxide reductase. Nature 427 : 541-544, 2004
PubMed
12) 森田隆司 : ビタミンKepoxide reductaseとビタミンK依存性炭酸固定反応. 別冊・医学のあゆみ血液疾患-state of arts, 坂田洋一ほか編, 医歯薬出版, 東京, 2005, pp.154-158
 
13) Sunnerhagen M, Forsen S, Hoffren AM et al : Structure of the Ca2+ -free Gla domain sheds light on membrane binding of blood coagulation proteins. Nat Struct Biol 2 : 504-509, 1995
PubMed
14) Soriano-Garcia M, Padmanabhan K, de Vos AM et al : The Ca2+ ion and membrane binding structure of the Gla domain of Ca-prothrombin fragment 1. Biochemistror 31 : 2554-2566, 1992
PubMed
15) Banner DW, D'Arcy A, Chene C et al : The crystal structure of the complex of blood coagulation factor VIIa with soluble tissue factor. Nature 380 : 41-46, 1996
PubMed
16) Zama T, Murata M, Watanabe R et al : A family with hereditary factor X deficiency with a point mutation Gla32 to Gln in the Gla domain (factor X Tokyo) . Br J Haematol 106 : 809-811, 1999
 
17) Huang M, Rigby AC, Morelli X et al : Structural basis of membrane binding by Gla domains of vitamin K-dependent proteins. Nat Struct Biol 10 : 751-756, 2003
PubMed
18) Sekiya F, Yamashita T, Atoda H et al : Regulation of the tertiary structure and function of coagulation factor IX by magnesium (II) ions. J Biol Chem 270 : 14325-14331, 1995
PubMed
19) Sekiya F, Yoshida M, Yamashita T et al : Magnesium (II) is a crucial constituent of the blood coagulation cascade. Potentiation of coagulant activities offactor IX by Mg2+ ions. J Biol Chem 271 : 8541-8544, 1996
 
20) Shikamoto Y, Morita T, Fujimoto Z et al : Crystal structure of Mg2+ -and Ca2+ -bound Gla domain of factor IX complexed with binding protein. J Biol Chem 278 : 24090-24094, 2003
PubMed
21) Imamura T, Potempa J, Tanase S et al : Activation of blood coagulation factor X by arginine-specific cysteine proteinases (gingipain-Rs) from Porphyromonas gingivalis. J Biol Chem 272 : 16062-16067, 1997
PubMed
22) Morita T : Proteases which activate factor X. In : Enzymes from snake venom, ed. by Bailey GS, Alaken, Colorado, 1998, pp.179-208
 
23) Altieri DC, Morrissey JH, Edgington TS : Adhesive receptor Mac-1 coordinates the activation of factor Xon stimulated cells of monocytic and myeloid differentiation : an alternative initiation of the coagulation protease cascade. Proc Natl Acad Sci USA 85 : 7462-7466, 1988
 
24) Yalamanchili P, Lu C, Oxvig C et αl : Folding and function of I domain-deleted Mac-1 and lymphocyte function-associated antigen-1. J Biol Chem 275 : 21877-21882, 2000
 
25) Mesri M, Plescia J, Altieri DC : Dual regulation of ligand binding by CD11b I domain. Inhibition of intercellular adhesion and monocyte procoagulant activity by a factor X-derived peptide. J Biol Chem 273 : 744-748, 1998
PubMed
26) Rezaie AR : Identification of basic residues in the heparin-binding exosite of factor Xa critical for heparin and factor Va binding. J Biol Chem 275 : 3320-3327, 2000
 
27) Rudolph AE, Porche-Sorbet R, Miletich JP : Definition of a factor Va binding site in factor Xa. J Biol Chem 276 : 5123-5128, 2001
PubMed
28) Rezaie AR, Kittur FS : The critical role of the 185-189-loop in the factor Xa interaction with Na+ and actor Va in the prothrombinase complex. J Biol Chem 279 : 48262-48269, 2004
 
29) 井上敬介, 森田隆司 : 第IX因子・第X因子. 止血・血栓・線溶, 松田道生ほか編, 中外医学社, 東京, 1994, pp.120-130
 
30) Kittur FS, Manithody C, Rezaie AR : Role of the Nterminal epidermal growth factor-like domain of factor X/Xa. J Biol Chem 279 : 24189-24196, 2004
 
31) Rezaie AR, Esmon CT : Asp-70→Lys mutant of factor X lacks high affinity Ca2+ binding site yet retains function. J Biol Chem 269 : 21495-21499, 1994
 
32) Rezaie AR, He X : Sodium binding site of factor Xa : role of sodium in the prothrombinase complex. Biochemistry 39 : 1817-1825, 2000
PubMed
33) Srivastava A, Wang J, Majumder R et al : Localization of phosphatidylserine binding sites to structural domains of factor Xa. J Biol Chem 277 : 1855-1863, 2002
PubMed
34) Han X, Huang ZF, Fiehler R et al : The protein Zdependent protease inhibitor is a serpin. Biochemistry 38 : 11073-11078, 1999
PubMed
35) Han X, Fiehler R, Broze GJ Jr : Isolation of a protein Z-dependent plasma protease inhibitor. Proc Natl Acad Sci USA 95 : 9250-9255, 1998
PubMed
36) 岩田広紀, 一瀬白帝 : プロテインZとZPIの分子病態学. 図説 血栓・止血・血管学-血栓症制圧のために-, 一瀬白帝編, 中外医学社, 東京, 2005, pp.510-516
 
37) Girard TJ, Warren LA, Novotny WF et al : Functional significance of the Kunitz-type inhibitory domains of lipoprotein-associated coagulation inhibitor. Nature 338 : 518-520, 1989
PubMed
38) 加藤久雄 : TFPIの基礎と臨床. 図説 血栓・止血・血管学-血栓症制圧のために-, 一瀬白帝編, 中外医学社, 東京, 2005, pp.498-509
 
39) Hackeng TM, Sere KM, Tans G et al : Protein S stimulates inhibition of the tissue factor pathway by tissue factor pathway inhibitor. Proc Natl Acad Sci USA 103 : 3106-3111, 2006
PubMed
40) Yamazaki Y, Morita T : Snake venom components affecting blood coagulation and the vascular system : structural similarities and marked diversity. Curr Pharm Des (in press) , 2006
 
41) 丸山征郎 : プロテアーゼ活性化受容体PAR. 図説 血栓・止血・血管学-血栓症制圧のために-, 一瀬白帝編, 中外医学社, 東京, 2005, pp.65-70
 
42) Pediaditakis P, Monga SP, Mars WM et al : Differential mitogenic effects of single chain hepatocyte growth factor (HGF) /scatter factor and HGF/NKl following cleavage by factor Xa. J Biol Chem 277 : 14109-14115, 2002
 
P.38 掲載の参考文献
1) Coughlin SR : Thrombin signalling and protease-ac-tivated receptors. Nature 407 : 258-264, 2000
 
2) Vu TK, Hung DT, Wheaton VI et al : Molecular cloning of a functional thrombin receptor reveals a novel proteolytic mechanism of receptor activation. Cell 64 : 1057-1068, 1991
PubMed
3) Matsushita K, Yamakuchi M, Morrell CN et al : Vascular endothelial growth factor regulation of Weibel-Palade-body exocytosis. Blood 105 : 207-214, 2005
PubMed
4) Boire A, Covic L, Agarwal A et al : PARI is a matrix metalloprotease-1 receptor that promotes invasion and tumorigenesis of breast cancer cells. Cell 120 : 303-313, 2005
 
5) Riewald M, Petrovan RJ, Donner A et al : Activation of endothelial cell protease activated receptor 1 by the protein C pathway. Science 296 : 1880-1882, 2002
PubMed
6) Tancharoen S, Sarker KP, Imamura T et al : Neuropeptide release from dental pulp cells by RgpB via proteinase-activated receptor-2 signaling. J Immunol 174 : 5796-5804, 2005
PubMed
7) Matsushita K, Imamura T, Tomikawa M et al : DX-9065a inhibits proinflammatory events induced by gingipains and factor Xa. J Periodontal Res 41 : 148-156, 2006
PubMed
8) Camerer E, Huang W, Coughlin SR : Tissue factor and factor X-dependent activation of protease-activated receptor 2 by factor VIIa. Proc Natl Acad Sci USA 97 : 5255-5260, 2000
PubMed
9) Altieri DC : Molecular cloning of effector cell protease receptor-1, a novel cell surface receptor for the protease factor Xa. J Biol Chem 269 : 3139-3142, 1994
PubMed
10) Zaman GJ, Conway EM : The elusive factor Xa receptor : failure to detect transcripts that correspond to the published sequence of EPR-1. Blood 96 : 145-148, 2000
 
11) Yamamoto T, Manome Y, Nakamura M et al : Downregulation of survivin expression by induction of the effector cell protease receptor-1 reduces tumor growth potential and results in an increased sensitivity to anticancer agents in human colon cancer. Eur J Cancer 38 : 2316-2324, 2002
 
12) Hezi-Yamit A, Wong PW, Bien-Ly N et al : Synergistic induction of tissue factor by coagulation factor Xa and TNF : evidence for involvement of negative regulatory signaling cascades. Proc Natl Acad Sci USA 102 : 12077-12082, 2005
PubMed
13) Senden NH, Jeunhomme TM, Heemskerk JW et al : Factor Xa induces cytokine production and expression of adhesion molecules by human umbilical vein endothelial cells. J Immunol 161 : 4318-4324, 1998
PubMed
14) Busch G, Seitz I, Steppich B et al : Coagulation factor Xa stimulates interleukin-8 release in endothelial cells and mononuclear leukocytes : implications in acute myocardial infarction. Arterioscler Thrormb Vasc Biol 25 : 461-466, 2005
PubMed
15) Koo BH, Kim DS : Factor Xa induces mitogenesis of vascular smooth muscle cells via autocrine production of epiregulin. J Biol Chem 278 : 52578-52586, 2003
PubMed
16) Rauch BH, Millette E, Kenagy RD et al : Thrombinand factor Xa-induced DNA synthesis is mediated by transactivation of fibroblast growth factor receptor-1 in human vascular smooth muscle cells. Circ Res 94 : 340-345, 2004
 
17) Imamura T, Potempa J, Tanase S et al : Activation of blood coagulation factor X by arginine-specific cysteine proteinases (gingipain-Rs) from Porphyromonas gingivalis. J Biol Chem 272 : 16062-16067, 1997
PubMed

Part2 Xa因子と疾患との関連

P.44 掲載の参考文献
1) Coughlin SR : Thrombin signaling and protease-activated receptors. Nature 407 : 258-264, 2000
PubMed
2) Versteeg HH, Ruf W : Emerging insights in tissue factor-dependent signaling events. Semin Thromb Hemost 32 : 24-32, 2006
PubMed
3) Nakajima T, Kitajima I, Shin H et al : Involvement of NF-κB activation in thrombin-induced human vascular smooth muscle cell proliferation, Biochem Biophys Res Commun 204 : 950-958, 1994
 
4) Covic L, Misra M, Badar J et al : Pepducin-based intervention of thrombin-receptor signaling and systemic platelet activation. Nat Med 8 : 1161-1165, 2002
PubMed
5) Arisato T, Sarker KP, Kawahara K et al : The agonist of the protease-activated receptor-1 (PAR) but not PAR3 mimics thrombin-induced vascular endothelial growth factor release in human smooth muscle cells. Cell Mol Life Sci 60 : 1716-1724, 2003
 
6) Boire A, Covic L, Agarwal A et al : PARI is a matrix metalloprotease-1 receptor that promotes invasion and tumorgenesis of breast cancer cells. Cell 120 : 303-313, 2005
 
7) Arribas J : Matrix metalloproteases and tumor invasion. N Engl J Med 352 : 2020-2021, 2005
PubMed
8) Ruf W, Dorfleutner A, Riewald M : Specificity of coagulation factor signaling. J Thromb Haemost 1 : 1495-1503, 2003
PubMed
9) Tancharoen S, Sarker KP, Imamura T et al : Neuropeptide release from dental pulp cells by RgpB via proteinase-activated receptor-2 signaling. J Immunol 174 : 5796-5804, 2005
PubMed
10) Noorbakhsh F, Tsutsui S, Vergnolle N et al : Proteinase-activated receptor 2 modulates neuroinflammation in experimental autoimmune encephalomyelitis and multiple sclerosis. J Exp Med 203 : 425-435, 2006
PubMed
11) Maeda K, Hirota M, Kimura Y et al : Proinflammatory role of trypsin and protease-activated receptor-2 in a rat model of acute pancreatitis. Pancreas 31 : 54-62, 2005
 
12) Kubitza D, Becka M, Mueck W et al : Safety, tolera. bility, pharmacodynamics, and pharmacokinetics of rivaroxaban-an oral, direct factor Xa inhibitor-are not affected by aspirin. J Clin Pharmacol 46 : 981-990, 2006
 
13) Ono T, Liu N, Makino T et al : Role of mesangial Factor V expression in crescent formation in rat experimental mesangioproliferative glomerulonephritis. J Pathol 204 : 229-238, 2004
PubMed
14) Tanaka M, Arai H, Liu N et al : Role of coagulation factor Xa and protease-activated receptor 2 in human mesangial cell proliferation. Kidney Int 67 : 2123-2133, 2005
PubMed
15) Vergnolle N, Wallace JL, Bunnett NW et al : Proteaseactivated receptors in inflammation, neuronal signaling and pain. Trends Pharmacol Sci 22 : 146-152, 2001
PubMed
16) Vergnolle N, Bunnett NW, Sharkey KA et al : Proteinase-activated receptor-2 and hyperalgesia : A novel pain pathway. Nat Med 7 : 821-826, 2001
PubMed
17) Kawabata A, Kawao N, Kuroda R et al : Peripheral PAR-2 triggers thermal hyperalgesia and nociceptive responses in rats. Neuroreport 12 : 715-719, 2001
PubMed
P.52 掲載の参考文献
1) Elodi S, Varadi K : Optimization of conditions for the catalytic effect of the factor IXa-factor VIII complex : probable role of the complex in the amplification of blood coagulation. Thromb Res 15 : 617-629, 1979
PubMed
2) Mann KG, Krishnaswamy S, Lawson JH : Surface-dependent hemostasis. Semin Hematol 29 : 213-226, 1992
PubMed
3) Tracy PB, Eide LL, Mann KG : Human prothrombinase complex assembly and function on isolated peripheral blood cell populations. J Biol Chem 260 : 2119-2124, 1985
PubMed
4) Radcliffe R, Nemerson Y : Activation and control of factor VII by activated factor X and thrombin. Isolation and characterization of a single chain form of factor VII. J Biol Chem 250 : 388-395, 1975
PubMed
5) Haley PE, Doyle MF, Mann KG : The activation of bovine protein C by factor Xa. J Biol Chem 264 : 16303-16310, 1989
PubMed
6) Bauer KA, Goodman TL, Kass BL et al : Elevated factor Xa activity in the blood of asymptomatic patients with congenital antithrombin deficiency. J Clin Invest 76 : 826-836, 1985
PubMed
7) auer KA, Weiss LM, Sparrow D et al : Aging-associated changes in indices of thrombin generation and protein C activation in humans. Normative Aging Study. J Clin Invest 80 : 1527-1534, 1987
 
8) Becker RC : The importance of factor Xa regulatory pathways in vascular thromboresistance : focus on protein Z. J Thromb Thrombolysis 19 : 135-137, 2005
 
9) Tabatabai A, Fiehler R, Broze GJ Jr : Protein Z circulates in plasma in a complex with protein Z-dependent protease inhibitor. Thromb Haemost 85 : 655-660, 2001
 
10) 松田保 : 止血・血栓の臨床, 新興医学出版社, 東京, 1996
 
11) Ogawa S, Gerlach H, Esposito C et al : Hypoxia modulates the barrier and coagulant function of cultured bovine endothelium. Increased monolayer permeability and induction of procoagulant properties. J Clin Invest 85 : 1090-1098, 1990
PubMed
12) Heit JA, Silverstein MD, Mohr DN et al : The epidemiology of venous thromboembolism in the community. Thromb Haemost 86 : 452-463, 2001
PubMed
13) Wiles N, Hunt BJ : Anticoagulation via anti-Factor Xa inhibition. Lupus 15 : 167-171, 2006
PubMed
14) Kniffin WD Jr, Baron JA, Barrett J et al : The epidemiology of diagnosed pulmonary embolism and deep venous thrombosis in the elderly. Arch Intern Med 154 : 861-866, 1994
PubMed
15) Wysokinski W, McBane R, Chesebro JH et al : Reversibility of platelet thrombosis in vivo. Quantitative analysis in porcine carotid arteries. Thromb Haemost 76 : 1108-1113, 1996
PubMed
16) Giesen PL, Rauch U, Bohrmann B et al : Blood-bornetissue factor : another view of thrombosis. Proc Natl Acd Sci USA 96 : 2311-2315, 1999
 
17) Komorowic E, McBane RD 2nd, Charlesworth J et al : Reduced high shear platelet adhesion to the vascular media : defective von Willebrand factor binding to the interstitial collagen. Thromb Haemost 87 : 763-770, 2000
 
18) Rezaie AR : Prothrombin protects factor Xa in the prothorombinase complex from inhibition by the heparin-antithrombin complex : Blood 97 : 2308-2313, 2001
PubMed
19) Karnicki K, McBane 2nd RD, Miller RS et al : Inhibition and reversal of platelet-rich arterial thrombus in vivo : direct vs. indirect factor Xa inhibition. J Throntb Haemost 2 : 2162-2169, 2004
 
20) Owen WG, Bichler J, Ericson D et al : Gating of thrombin in platelet aggregates by pO2-linked lowering of extracellular Ca2+ concentration. Biochemistry 34 : 9277-9281, 1995
PubMed
21) Hart RG, Halperin JL : Atrial fibrillation and stroke : concepts and controversies. Stroke 32 : 803-808, 2001
PubMed
22) 後藤信哉 : 心房細動における血栓発生機序とその診断. 血栓と循環14 : 42-45, 2006
 
23) Pineo GF, Brain MC, Gallus AS et al : Tumors, mucus production, and hypercoagulability. Ann NY Acad Sci 230 : 262-270, 1974
PubMed
24) De Cicco M : The prothrombotic state in cancer : pathogenic mechanisms. Crit Rev Oncol Hematol 50 : 187-196, 2004
 
25) Bick RL : Cancer-associated thrombosis. N Engl J Med 349 : 109-111, 2003
PubMed
26) Xu N, Dahlback B, Ohlin AK et al : Association of vitamin K-dependent coagulation proteins and C4b binding protein with triglyceride-rich lipoproteins of human plasma. Arterioscler Thromb Vasc Biol 18 : 33-39, 1998
PubMed
27) Simpson HC, Mann JI, Meade TW et al : Hypertrig-lyceridaemia and hypercoagulability. Lancet 1 : 786-790, 1983
 
28) Paton CM, Brandauer J, Weiss EP et al : Hemostatic response to postprandial lipemia before and after exercise training. J Appl Physiol 101 : 316-321, 2006
PubMed
29) Weitz JI, Bates SM : New anticoagulants. J Thromb Haemost 3 : 1843-1853, 2005
PubMed
30) Hampton T : New oral anticoagulants show promise. JAMA 295 : 743-744, 2006
PubMed
P.58 掲載の参考文献
1) Wada H : Disseminated intravascular coagulation. Clin Chim Acta 344 : 13-21, 2004
PubMed
2) Wallberg-Jonsson S, Cvetkovic JT, Sundqvist KG et al : Activation of the immune system and inflammatory activity in relation to markers of atherothrombotic disease and atherosclerosis in rheumatoid arthritis. J Rheumatol 29 : 875-882, 2002
PubMed
3) Robinson RA, Worfolk L, Tracy PB : Endotoxin enhances the expression of monocyte prothrombinase activity. Blood 79 : 406-416, 1992
PubMed
4) Sase T, Wada H, Kamikura Y et al : Tissue factor messenger RNA levels in leukocytes compared with tissue factor antigens in plasma from patients in hypercoagulable state caused by various diseases. Thromb Haemost 92 : 132-139, 2004
PubMed
5) Le Guyader A, Davis-Gorman G, Copeland JG et al : Aflow cytometric method for determining the binding of coagulation factor X to monocytes in whole human blood. J Immunol Methods 292 : 207-215, 2004
 
6) Ohkura N, Soe G, Kohno I et al : Monoclonal antibody specific for tissue factor pathway inhibitor (TFPI) -factor Xa complex : its characterization and application to plasmas from DIC and pre-DIC. Blood Coagul Fibrinolysis 10 : 309-319, 1999
PubMed
7) Okugawa Y, Wada H, Noda T et al : Increased plasma levels of tissue factor pathway inhibitor-activated factor X complex in patients with disseminated intravascular coagulation. Am J Hematol 65 : 210-214, 2000
PubMed
8) Frank RD, Schabbauer G, Holscher T et al : The synthetic pentasaccharide fondaparinux reduces coagulation, inflammation and neutrophil accumulation in kidney ischemia-reperfusion injury. J Thromb Haemost 3 : 531-540, 2005
PubMed
9) Olanders K, Borjesson A, Zhao X et al : Effects of anticoagulant treatment on intestinal ischaemia and reperfusion injury in rats. Acta Anaesthesiol Scand 49 : 517-524, 2005
PubMed
10) Chu AJ : Tissue factor mediates inflammation. Arch Biochem Biophys 440 : 123-132, 2005
PubMed
11) Strukova S : Blood coagulatiordependent inflammation. Coagulation-dependent inflammation and inflam-mation-dependent thrombosis. Front Biosci 11 : 59-80, 2006
 
12) Feistritzer C, Lenta R, Riewald M : Protease-activated receptors-1 and-2 can mediate endothelial barrier protection : role in factor Xa signaling. J Thromb Haemost 3 : 2798-2805, 2005
PubMed
13) Busch G, Seitz I, Steppich B et al : Coagulation factor Xa stimulates interleukin-8 release in endothelial cells and mononuclear leukocytes : implications in acute myocardial infarction. Arterioscler Thromb Vasc Biol 25 : 461-466, 2005
PubMed
14) Senden NH, Jeunhomme TM, Heemskerk JW et al : Factor Xa induces cytokine production and expression of adhesion molecules by human umbilical vein endothelial cells. J Immunol 161 : 4318-4324, 1998
PubMed
15) Matsushita K, Imamura T, Tomikawa M et al : DX-9065a inhibits proinflammatory events induced by gingipains and factor Xa. J Periodontal Res 41 : 148-156, 2006
PubMed
16) Hezi-Yamit A, Wong PW, BierLy N et al : Synergistic induction of tissue factor by coagulation factor Xa and TNF : evidence for involvement of negative regulatory signaling cascades. Proc Natl Acad Sci USA 102 : 12077-12082, 2005
 

Part3 Xa因子の制御機構

P.66 掲載の参考文献
1) Johnson DJ, Li W, Adams TE et al : Antithrombin-S195A factor Xa-heparin structure reveals the allosteric mechanism of antithrombin activation. EMBO J25 : 2029-2037, 2006
 
2) 城谷裕子, 小出武比古 : アンチトロンビンのプロテアーゼ阻害機構とヘパリンの作用機構-立体構造で見る動的構造変化-. 日血栓止血会誌10 : 93-99, 1999
 
3) Jin L, Abrahams JP, Skinner R et al : The anticoagulant activation of antithrombin by heparin. Proc Natl Acad Sci USA 94 : 14683-14688, 1997
PubMed
4) McCoy AJ, Pei XY, Skinner R et al : Structure of beta-antithrombin and the effect of glycosylation on antithrombin’s heparin affinity and activity. J Mol Biol 326 : 823-833, 2003
 
5) Izaguirre G, Olson ST : Residues Tyr253 and Glu255 in strand 30f beta-sheet C of antithrombin are key determinants of an exosite made accessible by heparin activation to promote rapid inhibition of factors Xa and IXa. J Biol Chem 281 : 13424-13432, 2006
 
6) 加藤久雄 : TFPIの基礎と臨床. 図説 血栓・止血・血管学, 一瀬白帝編. 中外医学社, 東京, 2005, pp.498-509
 
7) Dahm A, Van Hylckama Vlieg A, Bendz, B et al : Low levels of tissue factor pathway inhibitor (TFPI) increase the risk of venous thrombosis. Blood 101 : 4387-4392, 2003
PubMed
8) Broze GJ Jr : The rediscovery and isolation of TFPI. J Thromb Haemost 1 : 1671-1675, 2003
PubMed
9) Hackeng TM, Sere KM, Tans G et al : Protein S stimulates inhibition of the tissue factor pathway by tissue factor pathway inhibitor. Proc Natl Acad Sci USA 103 : 3106-3111, 2006
PubMed
10) Heeb MJ, Schuck P, Xu X : Protein S multimers and monomers each have direct anticoagulant activity. J Thromb Haemost 4 : 385-391, 2006
PubMed
11) Han X, Fiehler R, Broze GJ Jr : Isolation of a protein Z-dependent plasma protease inhibitor. Proc Natl Acad Sci USA 95 : 9250-9255, 1998
PubMed
12) Han X, Huang ZF, Fiehler R et al : The protein Zdependent protease inhibitor is a serpin. Biochemistry 38 : 11073-11078, 1999
PubMed
13) Han X, Fiehler R, Broze GJ Jr : Characterization of the protein Z-dependent protease inhibitor. Blood 96 : 3049-3055, 2000
PubMed
14) Rezaie AR, Manithody C, Yang L : Identification of factor Xa residues critical for interaction with protein Z-dependent protease inhibitor : both active site and exosite interactions are required for inhibition. J Biol Chem 280 : 32722-32728, 2005
PubMed
15) Water N, Tan T, Ashton F et al : Mutations within the protein Z-dependent protease inhibitor gene are associated with venous thromboembolic disease : a new form of thrombophilia. Br J Haematol 127 : 190-194, 2004
PubMed
16) Corral J, Gonzalez-Conejero R, Soria JM et al : A nonsense polymorphism in the protein Z-dependent protease inhibitor increases the risk for venous thrombosis. Blood 108 : 177-183, 2006
PubMed
17) Gris JC, Quere I, Dechaud H et al : High frequency of protein Z deficiency in patients with unexplained early fetal loss. Blood 99 : 2606-2608, 2002
PubMed
18) Refaai MA, Ahn C, Lu L et al : Protein Z and ZPI levels and cardiovascular events. J Thromb Haemost 4 : 1628-1629, 2006
PubMed
19) Yin ZF, Huang ZF, Cui J et al : Prothrombotic phenotype of protein Z deficiency. Proc Natl Acad Sci USA 97 : 6734-6738, 2000
PubMed

Part4 Xa阻害薬の薬理学的特徴をみる

P.74 掲載の参考文献
1) McLean J : The thromboplastic action of cephalin. Am J Physiol 41 : 250, 1916
 
2) 前川正 : I. 序言. ワーファリン, 前川正ほか編, メディカル・ジャーナル社, 東京, 1990, pp.1-9
 
3) Hirsh J, Raschke R : Heparin and low-molecular- weight heparin : the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 126 (suppl 3) : 188S-203S, 2004
 
4) Jorpes E : The chemistry of heparin. Biochem J 29 : 1817-1830, 1935
PubMed
5) Rosenberg RD, Damus PS : The purification and mechanism of action of human antithrombin-heparin cofactor. J Biol Chem 248 : 6490-6505, 1973
PubMed
6) 小嶋哲人 : ヘパリンの作用機序. 日常診療と血 3 : 41-46, 1993
 
7) 風間睦美 : II. 薬理, B. 臨床薬理. ワーファリン, 前川正ほか編 : メディカル・ジャーナル社, 東京, 1990, p.27-42
 
8) Weitz J, Crowther M : Direct thrombin inhibitors. Thromb Res 106 : V275-V284, 2002
PubMed
9) Hirsh J, Warkentin TE, Shaughnessy SG et al : Heparin and low-molecular-weight heparin : mechanisms of action, pharmacokinetics, dosing, monitoring, efficacy, and safety. Chest 119 (suppl 1) : 64S-94S, 2001
 
10) Andersson LO, Barrowcliffe TW, Holmer E et al : Anticoagulant properties of heparin fractionated by affinity chromatography on matrix-bound antithrombin III and by gel filtration. Thromb Res 9 : 575-583, 1976
PubMed
11) Alban S : From heparins to factor Xa inhibitors and beyond. Eur J Clin Invest 35 (suppl 1) : 12-20, 2005
 
12) Olson ST, Bjork I, Sheffer R et al : Role of the antithrombin-binding pentasaccharide in heparin acceleration of antithrombin-proteinase reactions. Resolution of the antithrombin conformational change contribution to heparin rate enhancement. J Biol Chem 267 : 12528-12538, 1992
PubMed
13) Alban S, Gastpar R : Plasma levels of total and free tissue factor pathway inhibitor (TFPI) as individual pharmacological parameters of various heparins. Thromb Haemost 85 : 824-829, 2001
PubMed
14) Weitz JI : Low-molecular-weight heparins. N Engl J Med 337 : 688-698, 1997
PubMed
15) Warkentin TE, Levine MN, Hirsh J et al : Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin. N Engl J Med 332 : 1330-1335, 1995
PubMed
16) Geerts WH, Heit JA, Clagett GP et al : Prevention of venous thromboembolism. Chest 119 (suppl 1) : 132S-175S, 2001
 
17) Choay J, Petitou M, Lormeau JC et al : Structure-activity relationship in heparin : asynthetic pentasaccharide with high affinity for antithrombin III and eliciting high anti-factor Xa activity. Biochem Biopyhsy Res Commun 116 : 492-499, 1983
 
18) Turpie AG, Gallus AS, Hoek JA : Asynthetic pentasaccharide for the prevention of deep-vein thrombosis after total hip replacement. N Engl J Med 344 : 619-625, 2001
 
19) Bauer KA, Hawkins DW, Peters PC et al : Fondaparinux, a synthetic pentasaccharide : the first in a new class of antithrombotic agents-the selective factor Xa inhibitors. Cardiovasc Drug Rev 20 : 37-52, 2002
 
20) Lormeau JC, Herault JP : The effect of the synthetic pentasaccharide SR 90107/ORG 31540 on thrombin generation ex vivo is uniquely due to ATIII-mediated neutralization of factor Xa. Thromb Haemost 74 : 1474-1477, 1995
PubMed
21) Alban S, Greinacher A : Role of sulfated polysaccharides in the pathogenesis of HIT. In : Heparin-Induced Thrombocytopenia, 2nd Edn, eds. by Warkentin TE et al, Marcel Dekker, New York, 2001, pp.167-187
 
22) Amiral J, Lormeau JC, Marfaing-Koka A et al : Absence of cross-reactivity of SR90107A/ORG31540 pentasaccharide with antibodies to heparin-PF4 complexes developed in heparin-induced thrombocytopenia. Blood Coagul Fibrinolysis 8 : 114-117, 1997
PubMed
23) Gerotziafas GT, Samama MM : Heterogeneity of synthetic factor Xa inhibitors. Curr Pharm Des 11 : 3855-3876, 2005
PubMed
P.81 掲載の参考文献
1) Ieko M, Tarumi T, Nakabayashi T et al : Factor Xa inhibitors : new antithrombotic agents and their characteristics. Front Biosci 11 : 232-248, 2006
PubMed
2) Schenk JF, Pindur G, Stephan B et al : 0n the prophylactic and therapeutic use of danaparoid sodium (Orgaran) in patients with heparin-induced thrombocytopenia. Clin Appl Thromb Hemost 9 : 25-32, 2003
 
3) Gerotziafas GT, Elalamy I, Depasse F et al : On the mechanism of inhibition of tissue factor pathway by the synthetic pentasaccharide during coagulation of human plasma. Blood Coagul Fibrinolysis 14 : 633-638, 2003
PubMed
4) Leone G, Rossi E, Leone AM et al : Novel antithrombotic agents : indirect synthetic inhibitors of factor Xa and direct thrombin inhibitors. Evidences from clinical studies. Curr Med Chem Cardiovasc Hematol Agents 2 : 311-326, 2004
PubMed
5) Bauersachs RM : Fondaparinux : an update on new study results. Eur J Clin Invest 35 (suppl 1) : S27-S32, 2005
 
6) Bal dit Sollier C, Kang C, Berge N et al : Activity of asynthetic hexadecasaccharide (SanOrg 123781A) in a pig model of arterial thrombosis. J Thromb Haemost 2 : 925-930, 2004
 
7) Gerotziafas GT, Samama MM : Heterogeneity of synthetic factor Xa inhibitors. Curr Pharm Des 11 : 3855-3876, 2005
PubMed
8) Ieko M, Tarumi T, Takeda M et al : Synthetic selective inhibitors of coagulation factor Xa strongly inhibit thrombin generation without affecting initial thrombin forming time necessary for platelet activation in hemostasis. J Thromb Haemost 2 : 612-618, 2004
PubMed
9) Majerus PW, Tollefsen DM, Shuman MA : The interaction of platelets with thrombin. In : Platelets in Biology and Pathology, ed. by Gordon JL, North-Holland Publishing, Amsterdam, 1976, pp.241-260
 
10) Morishima Y, Tanabe K, Terada Y et al : Antithrombotic and hemorrhagic effects of DX-9065a, a direct and selective factor Xa inhibitor : comparison with a direct thrombin inhibitor and antithrombin III-dependent anticoagulants. Thromb Haemost 78 : 1366-1371, 1997
 
P.89 掲載の参考文献
1) Okajima K, Yang WP, Okabe H et al : Role of leukocytes in the activation of intravascular coagulation in patients with septicemia. Am J Hematol 36 : 265-271, 1991
PubMed
2) Okajima K : The role of leukocytes in disseminated intravascular coagulation associated with sepsis. Sepsis 3 : 135-142, 2000
 
3) Bombeli T, Karsan A, Tait JF et al : Apoptotic vascular endothelial cells become procoagulant. Blood 89 : 2429-2442, 1997
PubMed
4) Niessen RW, Lamping RJ, Jansen PM et al : Antithrombin acts as negative acute phase protein as established with studies on HepG2 cells and in baboons. Thromb Haemost 78 : 1088-1092, 1997
PubMed
5) Levi M, van der Poll T, ten Cate H et al : The cytokine-mediated imbalance between coagulation and anticoagulant mechanisms in sepsis and endotoxemia. Eur J Clin Invest 27 : 3-9, 1997
PubMed
6) Jansen PM, Boermeester MA, Fischer E et al : Contribution of interleukin-1 and fibrinolysis, neutrophil degranulation, and the release of secretory-type phospholipase A2 in sepsis : studies in nonhuman primates after interleukin-1α administration and during lethal bacteremia. Blood 86 : 1027-1034, 1995
 
7) Salat C, Boekstegers P, Holler E et al : Hemostatic parameters in sepsis patients treated with anti-TNF α-monoclonal antibodies. Shock 6 : 233-237, 1996
 
8) Boermeester MA, van Leeuwen PA, Coyle SM et al : Interleukin-1 blockade attenuates mediator release and dysregulation of the hemostatic mechanisms during human sepsis. Arch Surg 130 : 739-748, 1995
PubMed
9) Iacoviello L, De Curtis A, D’Adamo MC et al : Prostacyclin is required for t-PA release after venous occlusion. Am J Physiol 266 : H429-H434, 1994
 
10) Harada N, Okajima K, Uchiba M et al : Ischemia/reperfusion-induced increase in the hepatic level of prostacyclin is mainly mediated by activation of capsaicin-Sensitive sensory neurons in rats. J Lab Clin Med 139 : 218-226, 2002
PubMed
11) Harada N, Okajima K, Uchiba M et al : Contribution of capsaicin-sensitive sensory neurons to stress-induced increases in gastric tissue levels of prostaglandins in rats. Am J Physiol Gastrointest Liver Physiol 285 : G1214-G1224, 2003
PubMed
12) Harada N, Okajima K, Liu W et al : Activated neutrophils impair gastric cytoprotection role of neutrophil elastase. Dig Dis Sci 45 : 1210-1216, 2000
PubMed
13) Okajima K, Harada N, Uchiba M et al : Neutrophil elastase contributes to the development of ischemia/reperfusion-induced liver injury by decreasing endothelial production of prostacyclin in rats. Am J Physiol Gastrointest Liver Physiol 287 : G1116-G1123, 2004
 
14) Furie B, Furie BC : Leukocyte crosstalk at the vascular wall. Thromb Haemost 78 : 306-309, 1997
PubMed
15) Okajima K, Harada N, Kushimoto S et al : Role of microthrombus formation in the development of ischemia/reperfusion-induced liver injury in rats. Thromb Haemost 88 : 473-480, 2002
PubMed
16) Okajima K, Harada N, Uchiba M : Microthrombus formation enhances tumor necrosis factor-α production in the development of ischemia/reperfusion-induced liver injury in rats. J Thromb Haemost 1 : 1316-1317, 2003
 
17) Riewald M, Ruf W : Orchestration of coagulation protease signaling by tissue factor. Trends Cardiovasc Med 12 : 149-154, 2002
PubMed
18) Taylor FB Jr, Chang A, Ruf W et al : Lethal E. coli septic shock is prevented by blocking tissue factor with monoclonal antibody. Circ Shock 33 : 127-134, 1991
PubMed
19) Enkhbaatar P, Okajima K, Murakami K et al : Recombinant tissue factor pathway inhibitor reduces lipopolysaccharide-induced pulmonary vascular injury by inhibiting leukocyte activation. Am J Respir Crit Care Med 162 : 1752-1759, 2000
PubMed
20) Isobe H, Okajima K, Uchiba M et al : Activated protein C prevents endotoxin-induced hypotension in rats by inhibiting excessive production of nitric oxide. Circulation 104 : 1171-1175, 2001
PubMed
21) Pawlinski R, Pedersen B, Schabbauer G et al : Role of tissue factor and protease-activated receptors in amouse model of endotoxemia. Blood 103 : 1342-1347, 2004
 
22) Kahn ML, Nakanishi-Matsui M, Shapiro MJ : Proteaseactivated receptors land 4 mediate activation of human platelets by thrombin. J Clin Invest 103 : 879-887, 1999
 
23) Uchiba M, Okajima K, Murakami K et al : Attenuation of endotoxin-induced pulmonary vascular injury antithrombin III. Am J Physiol 270 : L921-L930, 1996
PubMed
24) Harada N, Okajima K, Kushimoto S et al : Antithrombin reduces ischemia/reperfusion injury of rat liver by increasing the hepatic level of prostacyclin. Blood 93 : 157-164, 1999
PubMed
25) Isobe H, Okajima K, Uchiba M et al : Antithrombin prevents endotoxin-induced hypotension by inhibiting the induction of nitric oxide synthase in rats. Blood 99 : 1638-1645, 2002
PubMed
26) Mizutani A, Okajima K, Uchiba M et al : Antithrombin reduces ischemia/reperfusion-induced renal injury in rats by inhibiting leukocyte activation through promotion of prostacyclin production. Blood 101 : 3029-3036, 2003
PubMed
27) Uchiba M, Okajima K, Murakami K et al : Effects of plasma kallikrein specific inhibitor and active-site blocked factor VIIa on the pulmonary vascular injury induced by endotoxin in rats. Thromb Haemost 8 : 1209-1214, 1997
 
28) Harada N, Okajima K, Uchiba M : Dalteparin, a low molecular weight heparin, attenuates inflammatory responses and reduces ischemia-reperfusion-induced liver injury in rats. Crit Care Med 34 : 1883-1891, 2006
PubMed
29) Frank RD, Schabbauer G, Holscher T et al : The synthetic pentasaccharide fondaparinux reduces coagulation, inflammation and neutrophil accumulation in kidney ischemia-reperfusion injury. J Thromb Haemost 3 : 531-540, 2005
PubMed
30) Olanders K, Borjesson A, Zhao X et al : Effects of anticoagulant treatment on intestinal ischaemia and reperfusion injury in rats. Acta Anaesthesiol Scand 49 : 517-524, 2005
PubMed
31) Enkhbaatar P, Okajima K, Uchiba M et al : Recombinant tissue factor pathway inhibitor prevents lipopolysaccharide-induced systemic hypotension in rats by inhibiting excessive production of nitric oxide. Thromb Haemost 86 : 1573-1577, 2001
PubMed
32) Abraham E, Reinhart K, Opal S et al : Efficacy and safety of tifacogin (recombinant tissue factor path way inhibitor) in severe sepsis : arandomized trial. JAMA 290 : 238-247, 2003
 
P.96 掲載の参考文献
1) 中村真潮 : わが国における静脈血栓塞栓症の予防. 臨床画像 22 : 313-324, 2006
Medical*Online
2) 疑問に答える深部静脈血栓症予防ハンドブック, 江里健輔ほか編, 医歯薬出版, 東京, 2004, pp.1-207
 
3) Hemker HC, Choay J, Beguin S : Free factor Xa is on the main pathway of thrombin generation in clotting plasma. Biochim Biophys Acta 992 : 409-411, 1989
PubMed
4) 辻肇, 中川雅夫 : ヘパリン・低分子量ヘパリン. 抗凝固薬の適正な使い方, 櫻川信男ほか編, 医歯薬出版, 東京, 2001, pp.211-232
 
5) 島田和幸 : ヘパラン硫酸. 抗凝固薬の適正な使い方, 櫻川信男ほか編, 医歯薬出版, 東京, 2001, pp.301-308
 
6) van Boeckel CA, Petitou M : The unique antithrombin III binding domain of heparin : alead to new synthetic antithrombotics. Angew Chem Int Ed Engl 32 : 1671-1690, 1993
 
7) Herbert JM, Petitou M, Lormeau JC et al : SR90107A/Org31540, a novel anti-factor Xa antithrombotic agent. Cardiovasc Drug Rev 15 : 1-26, 1997
 
8) Olson ST, Bjork I, Sheffer R et al : Role of the antithrombin-binding pentasaccharide in heparin acceleration of antithrombin-proteinase reactions : resolution of the antithrombin conformational change contribution to heparin rate enhancement. J Biol Chem 267 : 12528-12538, 1992
PubMed
9) Turpie AG : Fondaparinux : a Factor Xa inhibitor for antithrombotic therapy. Expert Opin Pharmacother 5 : 1373-1384, 2004
PubMed
10) Carrie D, Caranobe C, Saivin S et al : Pharmacokinetic and antithrombotic properties of two pentasaccharides with high affinity to antithrombin III in the rabbit : comparison with CY216. Blood 84 : 2571-2577, 1994
PubMed
11) Lormeau JC, Herault JP : The effect of the synthetic pentasaccharide SR 90107/ORG 31540 on thrombin generation ex vivo is uniquely due to ATIII-mediated neutralization of factor Xa. Thromb Haemost 74 : 1474-1477, 1995
PubMed
12) Walenga JM, Bara L, Petitou M et al : The inhibition of the generation of thrombin and the antithrombotic effect of a pentasaccharide with sole antifactor Xa activity. Thromb Res 51 : 23-33, 1988
PubMed
13) Walenga JM, Jeske WP, Bara L et al : Biochemical and pharmacologic rationale for the development of asynthetic heparin pentasaccharide. Thromb Res 86 : 1-36, 1997
 
14) Lormeau JC, Herault Jp : Comparative inhibition of extrinsic and intrinsic thrombin generation by standard heparin, a low molecular weight heparin and the synthetic ATIII-binding pentasaccharide. Thromb Haemost 69 : 152-156, 176, 1993
PubMed
15) Walenga JM, Petitou M, Lormeau JC et al : Antithrombotic activity of a synthetic heparin pentasaccharide in a rabbit stasis thrombosis model using different thrombogenic challenges. Thromb Res 46 : 187-198, 1987
 
16) Hobbelen PM, van Dinther TG, Vogel GM et al : Pharmacological profile of the chemically synthesized antithrombin III binding fragment of heparin (pentasaccharide) in rats. Thromb Haemost 63 : 265-270, 1990
PubMed
17) Vogel GM, van Amsterdam RG, Kop WJ et al : Pentasaccharide and Orgaran arrest, whereas heparin delays thrombus formation in a rat arteriovenous shunt. Thromb Haemost 69 : 29-34, 1993
 
18) Vogel GM, van Amsterdam RG, Zandberg P et al : Two new closely related rat models with relevance to arterial thrombosis-efficacies of different antithrombotic drugs. Thromb Haemost 77 : 183-189, 1997
PubMed
19) Girolami B, Girolami A : Heparin-induced thrombocytopenia : areview. Semin Thromb Hemost 32 : 803-809, 2006
 
20) Amiral J, Lormeau JC, Marfaing-Koka A et al : Absence of cross-reactivity of SR90107A/ORG31540 pentasaccharide with antibodies to heparin-PF4 complexes developed in heparin-induced thrombocytopenia. Blood Coagul Fibrinolysis 8 : 114-117, 1997
PubMed
21) Ahmad S, Jeske WP, Walenga JM et al : Synthetic pentasaccharides do not cause platelet activation by antiheparin-platelet factor 4 antibodies. Clin Appl Thromb Hemost 5 : 259-266, 1999
 
22) Savi P, Chong BH, Greinacher A et al : Effect of fondaparinux on platelet activation in the presence of heparin-dependent antibodies : ablinded, comparative multicenter study with unfractionated heparin. Blood 105 : 139-144, 2005
PubMed

Part5 血栓塞栓症の病態と抗凝固療法の現状を探る

P.104 掲載の参考文献
1) Jackson SP, Schoenwaelder SM, Goncalves I et al : PI 3-kinase p110β : a new target for antithrombotic therapy. Nat Med 11 : 507-514, 2005
 
2) Fuster V, Moreno PR, Fayad ZA et al : Atherothrombosis and high-risk plaque : part I : evolving concepts. J Am Coll Cardiol 46 : 937-954, 2005
PubMed
3) Penz S, Reininger AJ, Brandl R et al : Human atheromatous plaques stimulate thrombus formation by activating Platelet glycoprotein VI. FASEB J 19 : 898-909, 2005
 
4) Salamonson Y : The ineffectiveness of a non-weight based heparin regimen in achieving therapeutic activated partial thromboplastin time (aPTT) in acute coronary syndrome. Aust Crit Care 13 : 128-133, 2000
PubMed
5) Scott LK, Grier LR, Conrad SA : Heparin-induced thrombocytopenia in a pediatric patient receiving extracorporeal membrane oxygenation managed with argatrobandouble dagger. Pediatr Crit Care Med 7 : 473-475, 2006
 
6) Becker RC, Alexander J, Dyke CK et al : Development of DX-9065a, a novel direct factor Xa inhibitor, in cardiovascular disease. Thromb Haemost 92 : 1182-1193, 2004
 
7) Saito H, Maruyama I, Shimazaki S et al : Efficacy and safety of recombinant human soluble thrombomodulin (ART-123) in disseminated intravascular coagulation : results of phase III randomized, double-blind, clinical trial. J Thromb Hamemost 5 : 31-41, 2007
PubMed
8) Olsson SB ; Executive Steering Committee on behalf of the SPORTIF III investigators : Stroke prevention with the oral direct thrombin inhibitor ximelagatran compared with warfarin in patients with non-valvular atrial fibrillation (SPORTIF III) : randomised controlled trial. Lancet 362 : 1691-1698, 2003
 
9) Halperin JL ; Executive Steering Committee, SPORTIF III and V investigators : Ximelagatran compared with warfarin for prevention of thromboembolism in patients with nonvalvular atrial fibrillation : Rationale, objectives, and design of a pair of clinical studies and baseline patient characteristics (SPORTIF III and V) . Am Heart 146 : 431-438, 2003
 
10) The Petro-ex Investigators. Safety and efficacy of extended exposure to several doses of a new oral direct thrombin inhibitor dabigatran etexilate in atrial fibrillation. Cerebrovasc Dis 21 (suppl 4) : 2 Abstract 5, 2006
 
11) Herbert JM, Petitou M, Lormeau JC et al : SR90107 A/Org31540, a novel anti-factor Xa antithrombotic agent. Cardiovasc Drug Rev 15 : 1-26, 1997
 
12) Frank RD, Holscher T, Schabbauer G et al : Anonanticoagulant synthetic pentasaccharide reduces inflammation in a murine model of kidney ischemiareperfusion injury. Thromb Haemost. 96 : 802-806, 2006
 
13) Matsushita K, Imamura T, Tomikawa M et al : DX-9065a inhibits proinflammatory events induced by gingipains and factor Xa. J Periodontal Res 41 : 148-156, 2006
PubMed
14) Eriksson BI, Borris L, Dahl OE et al ; ODIXa HIP Study Investigators : Oral, direct Xa inhibitor with BAY 59-7939 for the prevention of venous thromboembolism after total hip replacement. J Thromb Haemost 4 : 121-128, 2006
 
15) Iqbal O : Pharmacogenomics in anticoagulant drug development. Pharmacogenomics 3 : 823-828, 2002
PubMed
16) Stone GW, McLaurin BT, Cox DA et al : Bivalirudin for patients with acute coronary syndrome. N Engl J Med 355 : 2203-2216, 2006
 
P.115 掲載の参考文献
1) 小林隆夫, 中野赳, 佐久間聖仁ほか : 深部静脈血栓症/肺塞栓症 (静脈血栓塞栓症) サブグループ分担研究報告. 厚生労働省科学研究費補助金難治性疾患克服研究事業血液凝固異常症に関する調査研究平成17年度総括・分担研究報告書, 2006, pp.48-54
 
2) 小林隆夫 : 深部静脈血栓症と肺血栓塞栓症 (静脈血栓塞栓症) . 小林隆夫ほか編, 周産期の出血と血栓症-その基礎と臨床-, 金原出版, 東京, 2004, pp.276-304
 
3) 小林隆夫 : 産褥静脈血栓塞栓症. 日野原重明ほか監修, 看護のための最新医学講座第15巻産科疾患第2版, 中山書店, 東京, 2005, pp.348-363
 
4) Kimura R, Honda S, Kawasaki T et al : Protein S-K196E mutation as a genetic risk factor for deep vein thrombosis in Japanese patients. Blood 107 : 1737-1738, 2006
PubMed
5) Kinoshita S, Iida H, Inoue S et al : Protein S and protein C gene mutations in Japanese deep vein throm. bosis patients. Clin Biochem 38 : 908-915, 2005
 
6) Adachi T : Protein S and congenital protein S deficiency : the most frequent congenital thrombo-philia in Japanese. Curr Drug Targets 6 : 585-592, 2005
 
7) 佐久間聖仁, 白土邦男 : 急性肺血栓塞栓症. 日本臨牀 61 : 1706-1712, 2003
Medical*Online
8) Nicolaides AN, Gordon-Smith L : Arational approach to prevention. In : Thromboembolism, Aetiology, Advances in Prevention and Management, ed. by Nicolaides AN, Medical and Technical Publishing, Lancaster, 1975
 
9) 松本興治, 広瀬一, 林勝知ほか : 術後深部静脈血栓症に関する研究. 静脈学5 : 163-169, 1994
 
10) Sakon M, Maehara Y, Yoshikawa H et al : Incidence of venous thromboembolism following major abdominal surgery : amulti-center, prospective epidemio-logical study in Japan. J Thromb Haemost 4 : 581-586, 2006
 
11) Nakamura M, Fujioka H, Yamada N et al : Clinical characteristics of acute pulmonary thromboembolism in Japan : Results of a Multicenter Registry in the Japanese Society of Pulmonary Embolism Research. Clin Cardiol 24 : 132-138, 2001
PubMed
12) 黒岩政之, 古家仁, 瀬尾憲正ほか : 本邦における周術期肺塞栓症の発症頻度とその特徴-2002年度周術期肺血栓塞栓症発症調査報告第一報. 麻酔 53 : 454-463, 2004
 
13) 黒岩政之, 古家仁, 瀬尾憲正ほか : 周術期肺血栓塞栓症の発症頻度とその変化. 第11回肺塞栓症研究会抄録集, 2004, p.49
 
14) 瀬尾憲正 : 麻酔と肺血栓塞栓症の予防. 静脈学 16 : 33-39, 2005
 
15) 瀬尾憲正, 伊東誠, 入田和男ほか : 2004年日本麻酔科学会周術期肺塞栓症調査結果. 第12回肺塞栓症研究会抄録集, 2005, p.67
 
16) Anderson FA Jr, Wheeler HB, Goldberg RJ et al : A population-based perspective of the hospital incidence and case-fatality rates of deep vein thrombosis and pulmonary embolism : The Worcester DVT Study. Arch Intern Med 151 : 933-938, 1991
PubMed
17) 財団法人母子衛生研究会 : 母子保健の主なる統計, 2005, pp.78-80
 
18) 小林隆夫, 中林正雄, 石川睦男ほか : 産婦人科領域における深部静脈血栓症/肺血栓塞栓症-1991年から2000年までの調査成績-. 日産婦新生児血会誌14 : 1-24, 2005
 
19) 左近賢人 : 本邦における一般外科手術後急性肺塞栓症の現状と予防対策. Ther Res 24 : 610-612, 2003
Medical*Online
20) 藤田悟, 冨士武史, 三井忠夫ほか : 股関節または膝関節置換術後における深部静脈血栓症および肺塞栓症の発生頻度 : 予見的多施設共同研究. 整形外科51 : 745-749, 2000
 
21) 藤田悟 : 整形外科周術期の肺塞栓症. Ther Res 24 : 616-617, 2003
Medical*Online
22) 中野赳, 中村真潮 : 精神科病棟入院患者における肺塞栓症に関する検討. 厚生労働省科学研究費補助金難治性疾患克服研究事業血液凝固異常症に関する調査研究平成17年度総括・分担研究報告書, 2006, pp.129-130
 
23) Makino T, Asano Y, Hata N et al : International airports and pulmonary thromboembolism. Jpn J Thromb Hemost 12 : 480-486, 2001
 
24) Lapostolle E Surget V, Borron SW et al : Severe pulmonary embolism associated with air travel. N Engl J Med 345 : 779-783, 2001
 
25) 中野赳, 佐久間聖仁 : 新潟県中越地震後の肺塞栓症発症症例の検討. 厚生労働省科学研究費補助金難治性疾患克服研究事業血液凝固異常症に関する調査研究平成17年度総括・分担研究報告書, 2006, pp.125-128
 
26) 小林隆夫, 榛沢和彦 : 新潟県中越地震における深部静脈血栓症/肺塞栓症-エコー診による検討. 厚生労働省科学研究費補助金難治性疾患克服研究事業血液凝固異常症に関する調査研究平成17年度総括・分担研究報告書, 2006, pp.131-133
 
27) 小林隆夫, 黒岩政之 : 本邦の周術期肺塞栓症-発症頻度とその特徴. 厚生労働省科学研究費補助金難治性疾患克服研究事業血液凝固異常症に関する調査研究平成17年度総括・分担研究報告書, 2006, pp.134-138
 
28) Wauke K, Nagashima M, Kato N et al : Comparative study between thromboembolism and total knee arthroplasty with or without tourniquet in rheumatoid arthritis patients. Arch Orthop Trauma Surg 122 : 442-446, 2002
PubMed
29) 赤木将夫 : 静脈血栓塞栓症に対する危機管理をどう行うべきか. メディカルトリビューン紙2003年11月6日号
 
30) Parmet JL, Horrow JC, Berman AT et al : The incidence of large venous emboli during total knee arthroplasty without pneumatic tourniquet use. Anesth Analg 87 : 439-444, 1998
PubMed
31) 小林隆夫 : 整形外科におけるリスクマネジメント予防対策-術後肺血栓塞栓症. 骨・関節・靭帯18 : 801-811, 2005
 
32) 小林隆夫 : 妊婦のエマージェンシーケア-深部静脈血 栓症. 救急・集中医療17 : 903-908, 2005
 
33) 小林隆夫 : 婦人科の周術期静脈血栓症予防. 産婦人科手術17 : 143-148, 2006
 
34) 小林隆夫 : 肺血栓塞栓症の予防対策周術期管理. 血栓と循環14 : 60-65, 2006
 
35) 肺血栓塞栓症/深部静脈血栓症 (静脈血栓塞栓症) 予防ガイドライン作成委員会 : 肺血栓塞栓症/深部静脈血栓症 (静脈血栓塞栓症) 予防ガイドライン, メディカルフロントインターナショナルリミテッド, 東京, 2004, pp.1-96
 
36) Geerts WH, Pineo GF, Heit JA et al : Prevention of　venous thromboembolism : the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 126 (3 suppl) : 338S-400S, 2004
 
P.125 掲載の参考文献
1) Gulba DC, Schmid C, Borst HG et al : Medical compared with surgical treatment for massive pulmonary embolism. Lancet 343 : 576-577, 1994
PubMed
2) Geerts WH, Heit JA, Clagett GP et al : Prevention of venous thromboembolism. Chest 119 : 132S-175S, 2001
PubMed
3) Geerts WH, Pineo GF, Heit JA et al : Prevention of venous thromboembolism : The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 126 : 338S-400S, 2004
PubMed
4) 肺血栓塞栓症/深部静脈血栓症 (静脈血栓塞栓症) 予防ガイドライン作成委員会 : 肺血栓塞栓症/深部静脈血栓症 (静脈血栓塞栓症) 予防ガイドライン. メディカルフロントインターナショナルリミテッド, 東京, 2004
 
5) Samama MM, Cohen AT, Darmon JY et al : Acomparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients. N Engl J Med 341 : 793-800, 1999
 
6) Nicolaides AN, Breddin HK, Farees J et al : Prevention of venous thromboembolism. International Consensus Statement. Guidelines complied in accordance with the scientific evidence. Int Angiol 20 : 1-37, 2001
 
7) 山田典一 : わが国の内科領域における静脈血栓塞栓症の現状. Therapeutic Research 24 : 618-620, 2003
Medical*Online
8) Levine MN, Gent M, Hirsh J et al : The thrombogenic effect of anticancer drug therapy in women with stage II breast cancer. N Engl J Med 318 : 404-407, 1988
PubMed
9) Kniffin WD Jr, Baron JA, Barrett J et al : The epidemiology of diagnosed pulmonary embolism and deep venous thrombosis in the elderly. Arch Intern Med 154 : 861-866, 1994
PubMed
10) Levine M, Hirsh J, Gent M et al : Double-blind randomized trial of very-low-dose warfarin for prevention of thromboembolism in stage IV breast cancer. Lancet 343 : 886-889, 1994
PubMed
11) Cohen AT, Davidson BL, Gallus AS et al : Fondaparinux for the prevention of VTE in acutely ill medical patients. Blood 102 : 15a, 2003
 
12) 循環器病の診断と治療に関するガイドライン (2002-2003年度合同研究班報告) 肺血栓塞栓症および深部静脈血栓症の診断・治療・予防に関するガイドライン. Circ J 68 (suppl IV) : 1079-1134, 2004
 
13) Goldstein LB, Adams R, Alberts MJ et al ; American Heart Association ; American Stroke Association Stroke Council : Primary prevention of ischemic stroke : aguideline from the American Heart Association/American Stroke Association Stroke Council : cosponsored by the Atherosclerotic Peripheral Vascular Disease Interdisciplinary Working Group ; Cardiovascular Nursing Council ; Clinical Cardiology Council ; Nutrition, Physical Activity, and Metabolism Council ; and the Quality of Care and Outcomes Research Interdisciplinary Working Group. Circulation 113 : e873-e923, 2006
 
14) Sato H, Ishikawa K, Kitabatake A et al ; Japan Atrial Fibrillation Stroke Trial Group : Low-dose aspirin for prevention of stroke in low-risk patients with atrial fibrillation : Japan Atrial Fibrillation Stroke Trial. Stroke 37 : 447-451, 2006
PubMed
15) Beppu S, Park YD, Sakakibara H et al : Clinical features of intracardiac thrombosis based on echocardiographic observation. Jpn Circ J 48 : 75-82, 1984
PubMed
16) Hart RG, Benavente O, McBride R et al : Antithrombotic therapy to prevent stroke in patients with atrial fibrillation : ameta-analysis. Ann Intern Med 131 : 492-501, 1999
 
17) Adjusted-dose warfarin versus low-intensity, fixeddose warfarin plus aspirin for high-risk patients with atrial fibrillation : Stroke Prevention in Atrial Fibrillation III randomised clinical trial. Lancet 348 : 633-638, 1996
PubMed
18) Fuster V, Ryden LE, Asinger RW et al ; American College of Cardiology/American Heart Association Task Force on Practice Guidelines ; European Society of Cardiology Committee for Practice Guidelines and Policy Conferences (Committee to Develop Guidelines for the Management of Patients With Atrial Fibrillation) ; North American Society of Pacing and Electrophysiology : ACC/AHA/ESC Guidelines for the Management of Patients With Atrial Fibrillation : Executive Summary A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines and Policy Conferences (Committee to Develop Guidelines for the Management of Patients With Atrial Fibrillation) Developed in Collaboration With the North American Society of Pacing and Electrophysiology. Circulation 104 : 2118-2150, 2001
 
19) 循環器病の診断と治療に関するガイドライン (1999-2000年度合同研究班報告) 心房細動治療 (薬物) ガイドライン. Jpn Circ J 65 (suppl V) : 931-998, 2001
 
20) 循環器病の診断と治療に関するガイドライン (2002-2003年度合同研究班報告) 循環器疾患における抗凝固・抗血小板療法に関するガイドライン. Circ J 68 (suppl IV) : 1153-1219, 2004
 
P.131 掲載の参考文献
1) 川島康男, 瀬尾憲正, 巌康秀ほか : 周術期深部静脈血栓症術中致死的肺塞栓の現況-日本麻酔科学会麻酔関連偶発症例調査より. 日臨麻会誌23 : 98-109, 2003
 
2) 循環器病の診断と治療に関するガイドライン (2002-2003年度合同研究班報告) 肺血栓塞栓症および深部静脈血栓症の診断・治療・予防に関するガイドライン. Circ J 68 (suppl IV) : 1079-1134, 2004
 
3) Virchow R : Gesammelte Abhandlungen zur wissenschaftlichen Medizin. Meidinger Sohn, Frankfurt, 1856
 
4) Geerts WH, Heit JA, Clagett GP et al : Prevention of venous thromboembolism. Chest 119 : 132S-175S, 2001
PubMed
5) Polgar J, Matuskova J, Wagner DD : The P-selectin, tissue factor, coagulation triad. J Thromb Haemost 3 : 1590-1596, 2005
 
6) Biro E, Sturk-Maquelin KN, Vogel GM et al : Human cell-derived microparticles promote thrombus formation in vivo in a tissue factor-dependent manner. J Thromb Haemost 1 : 2561-2568, 2003
 
7) Satta N, Toti F, Feugeas O et al : Monocyte vesiculation is a possible mechanism for dissemination of membrane-associated procoagulant activities and adhesion molecules after stimulation by lipopolysaccharide. J Immunol 153 : 3245-3255, 1994
PubMed
8) 左近賢人 : 一般外科領域における静脈血栓塞栓症の頻度と予防. 静脈学16 : 19-25, 2005
 
9) Sakon M, Maehara Y, Yoshikawa H et al : Incidence of venous thromboembolism following major abdominal surgery : amulti-center, prospective epidemiological study in Japan. J Thromb Haemost 4 : 581-586, 2006
 
10) Warkentin TE, Greinacher A : Heparin-induced thrombocytopenia : recognition, treatment, and prevention : the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 126 : 311S-337S, 2004
PubMed
11) Pouplard C, May MA, Iochmann S et al : Antibodies to platelet factor 4-heparin after cardiopulmonary bypass in patients anticoagulated with unfractionated heparin or a low-molecular-weight heparin : clinical implications for heparirinduced thrombocytopenia. Circulation 99 : 2530-2536, 1999
PubMed
12) Warkentin TE, Cook RJ, Marder VJ et al : Anti-platelet factor 4/heparin antibodies in orthopedic surgery patients receiving antithrombotic prophylaxis with fondaparinux or enoxaparin. Blood 106 : 3791-3796, 2005
PubMed
13) Ridker PM, Goldhaber SZ, Danielson E et al ; PREVENT Investigators : Long-term, low-intensity warfarin therapy for the prevention of recurrent venous thromboembolism. N Engl J Med 348 : 1425-1434, 2003
PubMed
14) Shetty HG, Backhouse G, Bentley DP et al : Effective reversal of warfarin-induced excessive anticoagulation with low dose vitamin K1. Thromb Haemost 67 : 13-15, 1992
PubMed
15) Stein PD, Hull RD, Raskob G : Risks for major bleeding from thrombolytic therapy in patients with acute pulmonary embolism. Consideration of noninvasive management. Ann Intern Med 121 : 313-317, 1994
PubMed
16) Kanter DS, Mikkola KM, Patel SR et al : Thrombolytic therapy for pulmonary embolism. Frequency of intracranial hemorrhage and associated risk factors. Chest 111 : 1241-1245, 1997
PubMed
17) Agnelli G, Becattini C, Kirschstein T : Thrombolysis vs heparin in the treatment of pulmonary embolism : aclinical outcome-based meta-analysis. Arch Intern Med 162 : 2537-2541, 2002
 

Part6 臨床応用におけるXa阻害薬の位置づけを探る

P.139 掲載の参考文献
1) Weitz JI : Low-molecular-weight heparins. N Engl J Med 337 : 688-698, 1997
PubMed
2) Turpie AG, Gallus AS, Hoek JA ; Pentasaccharide Investigators : Asynthetic pentasaccharide for the prevention of deep-vein thrombosis after total hip replacement. N Engl J Med 344 : 619-625, 2001
 
3) Falati S, Gross P, Merrill-Skoloff G et al : Real-time in vivo imaging of platelets, tissue factor and fibrin during arterial thrombus formation in the mouse. Nat Med 8 : 1175-1181, 2002
PubMed
4) Holme PA, Brosstad F, Solum NO : Platelet-derived microvesicles and activated platelets express factor Xa activity. Blood Coagul Fibrinolysis 6 : 302-310, 1995
PubMed
5) Monroe DM, Hoffman M, Roberts HR : Platelets and thrombin generation. Arterioscler Thromb Vasc Biol 22 : 1381-1389, 2002
PubMed
6) Buller HR, Davidson BL, Decousus H et al ; Matisse Investigators : Fondaparinux or enoxaparin for the initial treatment of symptomatic deep venous thrombosis : arandomized trial. Ann Intern Med 140 : 867-873, 2004
 
7) Eriksson BI, Borris L, Dahl OE et al ; ODIXa-HIP Study Investigators : Oral, direct Factor Xa inhibition with BAY 59-7939 for the prevention of venous thromboembolism after total hip replacement. J Thromb Haemost 4 : 121-128, 2006
 
8) Turpie AG, Fisher WD, Bauer KA et al ; OdiXa-Knee Study Group : BAY 59-7939 : an oral, direct factor Xa inhibitor for the prevention of venous thromboembolism in patients after total knee replacement. A phase II dose-ranging study. J Thromb Haemost 3 : 2479-2486, 2005
 
9) Goto S : Understanding the mechanism and prevention of arterial occlusive thrombus formation by antiplatelet agents. Curr Med Chem Cardiovasc Hematol Agents 2 : 149-156, 2004
PubMed
10) Simoons ML, Bobbink IW, Boland J et al : Adosefinding study of fondaparinux in patients with non-ST-segment elevation acute coronary syndromes : the Pentasaccharide in Unstable Angina (PENTUA) Study. J Am Coll Cardiol 43 : 2183-2190, 2004
PubMed
11) Yusuf S, Mehta SR, Chrolavicius S et al : Effects of fondaparinux on mortality and reinfarction in patients with acute ST-segment elevation myocardial infarction : the OASIS-6 randomized trial. JAMA 295 : 1519-1530, 2006
PubMed
12) Dyke CK, Becker RC, Kleiman NS et al : First experience with direct factor Xa inhibition in patients with stable coronary disease : apharmacokinetic and pharmacodynamic evaluation. Circulation 105 : 2385-2391, 2002
 
P.147 掲載の参考文献
1) Eriksson BI, Bauer KA, Lassen MR et al : Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after hip-fracture surgery. N Engl J Med 345 : 1298-1304, 2001
PubMed
2) Lassen MR, Bauer KA, Eriksson BI et al : Postoperative fondaparinux versus preoperative enoxaparin for prevention of venous thromboembolism in elective hip-replacement surgery : arandomised doubleblind comparison. Lancet 359 : 1715-1720, 2002
PubMed
3) Turpie AG, Bauer KA, Eriksson BI et al : Postoperative fondaparinux versus postoperative enoxaparin for prevention of venous thromboembolism after elective hip-replacement surgery : arandomised doubleblind trial. Lancet 359 : 1721-1726, 2002
PubMed
4) Bauer KA, Eriksson BI, Lassen MR et al : Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after elective major knee surgery. N Engl J Med 345 : 1305-1310, 2001
PubMed
5) Turpie AG, Bauer KA, Eriksson BI et al : Fondaparinux vs. enoxaparin for the prevention of venous thromboembolism in major orthopedic surgery : a meta-analysis of 4 randomized double-blind studies. Arch Intern Med 162 : 1833-1840, 2002
PubMed
6) Eriksson BI, Lassen MR ; PENTasaccharide in Hip-FRActure Surgery Plus Investigators : Duration of prophylaxis against venous thromboembolism with fondaparinux after hip fracture surgery : a multicenter, randomized, placebo-controlled, double-blind study. Arch Intern Med 163 : 1337-1342, 2003
PubMed
7) Geerts WH, Pineo GF, Heit JA et al : Prevention of venous thromboembolism : The seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 126 (3 suppl) : 338S-400S, 2004
 
8) Cohen AT, Davidson BL, Gallus AS et al ; ARTEMIS Investigators : Efficacy and safety of fondaparinux for the prevention of venous thromboembolism in older acute medical patients : randomised placebo controlled trial. BMJ 332 : 325-329, 2006
PubMed
9) Agnelli G, Bergqvist D, Cohen AT et al ; PEGASUS investigators : Randomized clinical trial of postoperative fondaparinux versus perioperative dalteparin for prevention of venous thromboembolism in highrisk abdominal surgery. Br J Surg 92 : 1212-1220, 2005
PubMed
10) Buller HR, Davidson BL, Decousus H et al ; Matisse Investigators : Fondaparinux or enoxaparin for the initial treatment of symptomatic deep venous thrombosis : arandomized trial. Ann Intern Med 140 : 867-873, 2004
 
11) Buller HR, Davidson BL, Decousus H et al ; Matisse Investigators : Subcutaneous fondaparinux versus intravenous unfractionated heparin in the initial treatment of pulmonary embolism. N Engl J Med 349 : 1695-1702, 2003
PubMed
12) Herbert JM, Herault JP, Bernat A et al : Biochemical and pharmacological properties of SANORG 34006, a potent and long-acting synthetic pentasaccharide. Blood 91 : 4197-4205, 1998
PubMed
13) PERSIST investigators : Anovel long-acting synthetic factor Xa inhibitor (SanOrg34006) to replace warfarin for secondary prevention in deep vein thrombosis : aphase II evaluation. J Thromb Haemost 2 : 47-53, 2004
 
14) Ferguson, JJ : Meeting highlights : American Heart Association scientific sessions 2001. Circulation 105 : e37-e41, 2002
 
15) Yusuf S, Mehta SR, Chrolavicius S et al ; Fifth Organization to Assess Strategies in Acute Ischemic Syndromes Investigators : Comparison of fondaparinux and enoxaparin in acute coronary syndromes. N Engl J Med 354 : 1464-1476, 2006
PubMed
16) Coussement PK, Bassand JP, Convens C et al : A synthetic factor-Xa inhibitor (ORG31540/SR9017A) as an adjunct to fibrinolysis in acute myocardial infarction : the PENTALYSE study. Eur Heart J 22 : 1716-1724, 2001
PubMed
17) Yusuf S, Mehta SR, Chrolavicius S et al ; OASIS-6 Trial Group : Effects of fondaparinux on mortality and reinfarction in patients with acute ST-segment elevation myocardial infarction : the OASIS-6 randomized trial. JAMA 295 : 1519-1530, 2006
PubMed
P.153 掲載の参考文献
1) 小林隆夫, 中野赳, 佐久間聖仁ほか : 深部静脈血栓症/肺塞栓症 (静脈血栓塞栓症) サブグループ分担研究報告. 厚生労働省科学研究費補助金難治性疾患克服研究事業 血液凝固異常症に関する調査研究平成17年度総括・分担研究報告書pp.48-54, 2006
 
2) 肺血栓塞栓症/深部静脈血栓症 (静脈血栓塞栓症) 予防ガイドライン作成委員会 : 肺血栓塞栓症/深部静脈血栓症 (静脈血栓塞栓症) 予防ガイドライン. メデイカルフロントインターナショナルリミテッド, 東京, 2004, pp.1-96
 
3) 黒岩政之, 古家仁, 瀬尾憲正ほか : 本邦における周術期肺塞栓症の発症頻度とその特徴-2002年度周術期肺血栓塞栓症発症調査報告第一報. 麻酔53 : 454-463, 2004
 
4) 黒岩政之, 古家仁, 瀬尾憲正ほか : 2003年周術期肺血栓塞栓症発症アンケート調査結果からみた本邦における発症頻度とその特徴-(社)日本麻酔科学会肺塞栓症研究ワーキンググループ報告-. 麻酔54 : 822-828, 2005
 
5) 黒岩政之, 古家仁, 瀬尾憲正ほか : 2004年周術期肺塞栓症発症調査結果からみた本邦における周術期肺血栓塞栓症発症頻度とその特徴-(社)日本麻酔科学会肺塞栓 症研究ワーキンググループ報告-. 麻酔55 : 1031-1038, 2006
 
6) Geerts WH, Pineo GF, Heit JA et al : Prevention of venous thromboembolism : the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 126 (3 suppl) : 338S-400S, 2004
 
7) Geerts WH, Heit JA, Clagett GP et al : Prevention of venous thromboembolism. Chest 119 (1 suppl) : 132S-175S, 2001
 
8) Nicolaides AN, Breddin HK, Fareed J et al : Prevention of venous thromboembolism. International Consensus Statement. Guidelines compiled in accordance with the scientific evidence. Int Angiol 20 : 1-37, 2001
PubMed
P.164 掲載の参考文献
1) Tapson VF, Witty LA : Massive pulmonary embolism. Diagnostic and therapeutic strategies. Clin Chest Med 16 : 329-340, 1995
PubMed
2) Barritt DW, Jordan SC : Anticoagulant drugs in the treatment of pulmonary embolism. A controlled trial. Lancet 1 : 1309-1312, 1960
PubMed
3) Ota M, Nakamura M, Yamada N et al : Association between antithrombotic treatments and prognosis of patients with acute pulmonary thromboembolism in Japan. Circ J 67 : 612-617, 2003
PubMed
4) 循環器病の診断と治療に関するガイドライン (2002-2003年度合同研究班報告) 肺血栓塞栓症および深部静脈血栓の診断・治療・予防に関するガイドライン. Circ J68 (suppl IV) : 1079-1152, 2004
 
5) Jerjes-Sanchez C, Ramirez-Rivera A, de Lourdes Garcia M et al : Streptokinase and Heparin versus Heparin Alone in Massive Pulmonary Embolism : A Randamized Controlled Trial. J Thromb Thrombolysis 2 : 227-229, 1995
 
6) Bottiger BW, Bohrer H, Bach A et al : Bolus injection of thrombolytic agents during cardiopulmonary resuscitation for massive pulmonary embolism. Resuscitation 28 : 45-54, 1994
PubMed
7) Konstantinides S, Geibel A, Heusel G et al : Heparin plus alteplase compared with heparin alone in patients with submassive pulmonary embolism. N Engl J Med 347 : 1143-1150, 2002
PubMed
8) Wan S, Quinlan DJ, Agnelli G et al : Thrombolysis compared with heparin for the initial treatment of pulmonary embolism : a meta-analysis of the randomized controlled trials. Circulation 110 : 744-749, 2004
PubMed
9) Sakuma M, Nakamura M, Nakanishi N et al : Inferior vena cava filter is a new additional therapeutic option to reduce mortality from acute pulmonary embolism. Circ J 68 : 816-821, 2004
PubMed
10) Girard P, Musset D, Parent F et al : High prevalence of detectable deep venous thrombosis in patients with acute pulmonary embolism. Chest 116 : 903-908, 1999
PubMed
11) 丹羽明博 : 内科的保存療法 ; 急性肺血栓塞栓症-その診断から治療まで-. Heart View 10 : 800-804, 2006
 
12) Ridker PM, Goldhaber SZ, Danielson E et al : Long-term, low-intensity warfarin therapy for the prevention of recurrent venous thromboembolism. N Engl J Med 348 : 1425-1434, 2003
PubMed
13) Kearon C, Ginsberg JS, Kovacs MJ et al : Comparison of low-intensity warfarin therapy with conventional-intensity warfarin therapy for long-term prevention of recurrent venous thromboembolism. N Engl J Med 349 : 631-639, 2003
PubMed
14) Kearon C, Gent M, Hirsh J et al : Acomparison of three months of anticoagulation with extended anticoagulation for a first episode of idiopathic venous thromboembolism. N Engl J Med 340 : 901-907, 1999
 
15) Schulman S, Rhedin AS, Lindmarker P et al : Acom. parison of six weeks with six months of oral anticoagulant therapy after a first episode of venous thromboembolism. N Engl J Med 332 : 1661-1665, 1995
 
16) Schulman S, Granqvist S, Holmstrom M et al : The duration of oral anticoagulant therapy after a second episode of venous thromboembolism. N Engl J Med 336 : 393-398, 1997
PubMed
17) Agnelli G, Prandoni P, Santamaria MG et al : Three months versus one year of oral anticoagulant therapy for idiopathic deep venous thrombosis. N Engl J Med 345 : 165-169, 2001
PubMed
18) Robinson DM, Wellington K : Fondaparinux sodium : areview of its use in the treatment of acute venous thromboembolism. Am J Cardiovasc Drugs 5 : 335-346, 2005
 
19) Keam SJ, Goa KL : Fondaparinux sodium. Drugs 62 : 1673-1685, 2002
PubMed
20) Buller HR, Davidson BL, Decousus H et al ; The Matisse Investigators : Subcutaneous fondaparinux versus intravenous unfractionated heparin in the treatment of pulmonary embolism. N Engl J Med 349 : 1695-1702, 2003
PubMed
21) Buller HR, Davidson BL, Decousus H et al ; The Matisse Investigators : Fondaparinux or enoxaparin for the initial treatment of symptomatic deep venous thrombosis : aramdomized trial. Ann Intern Med 140 : 867-873, 2004
 
22) Agnelli G, Bergqvist D, Cohen AT et al : Randomized clinical trial of postoperative fondaparinux versus perioperative dalteparin for prevention of venous thromboembolism in high-risk abdominal surgery. Br J Surg 92 : 1212-1220, 2005
PubMed
P.173 掲載の参考文献
1) Hirsh J, Warkentin TE, Shaughnessy SG et al : Heparin and low-molecular-weight heparin : mechanisms of action, pharmacokinetics, dosing, monitoring, efficacy, and safety. Chest 119 (1 suppl) : 64S-94S, 2004
 
2) Warkentin TE, Chong BH, Greinacher A : Heparininduced thrombocytopenia : towards consensus. Thromb Haemost 79 : 1-7, 1998
PubMed
3) 松尾美也子 : ヘパリン起因性血小板減少症の検査室診断. 日血栓止血会誌13 : 284-288, 2002
 
4) Makhoul RG, Greenberg CS, McCann RL : Heparinassociated thrombocytopenia and thrombosis : aserious clinical problem and potential solution. J Vasc Surg 4 : 522-528, 1986
 
5) Warkentin TE, Kelton JG : Temporal aspects of heparin-induced thrombocytopenia. N Engl J Med 344 : 1286-1292, 2001
PubMed
6) Warkentin TE, Kelton JG : Delayed-onset heparininduced thrombocytopenia and thrombosis. Ann Intern Med 135 : 502-506, 2001
PubMed
7) Francis JL, Palmer GJ 3rd, Moroose R et al : Comparision of bovine and porcine heparin in heparin antibody formation after cardiac surgery. Ann Thorac Surg 75 : 17-22, 2003
 
8) Walls JT, Curtis JJ, Silver D et al : Heparin-induced thrombocytopenia in open heart surgical patients : sequelae of late recognition. Ann Thorac Surg 53 : 787-791, 1992
PubMed
9) Warkentin TE, Sheppard JA, Horsewood P et al : Impact of the patient population on the risk of heparin-induced thrombocytopenia. Blood 96 : 1703-1708, 2000
PubMed
10) Fohlen-Walter A, De Maistre E, Mulot A et al : Does negative heparin-platelet 4 enzyme-linked immunosorbent assay effectively exclude heparin-induced thrombocytopenia? J Thromb Haemost 1 : 1844-1845, 2003
PubMed
11) Amiral J, Marfaing-Koka A, Wolf M et al : Presence of auto-antibodies to interleukin-8 and neutrophil activating peptide-2 in patients with heparin-associated thrombocytopenia. Blood 88 : 410-416, 1996
 
12) Regnault V, de Maistre E, Carteaux JP et al : Platelet activation induced by human antibodies to interleukin-8. Blood 101 : 1419-1421, 2003
PubMed
13) Pouplard C, Amiral J, Borg JY et al : Decision analysis for use of platelet aggregation test, carbon 14-serotonin release assay, and heparin-factor 4 enzyme-linked immunosorbent assay for diagnosis of heparin-induced thrombocytopenia. Am J Clin Pathol 111 : 700-706, 1999
PubMed
14) Zwicker JI, Uhl L, Huang WY et al : Thrombosis and ELISA optical density values in hospitalized patients with heparirinduced thrombocytopenia. J Thromb Haemost 2 : 2133-2137, 2004
PubMed
15) Greinacher A, Eichler P, Lubenow N et al : Heparininduced thrombocytopenia with thromboembolic complications : meta-analysis of 2 prospective trials to assess the value of parenteral treatment with lepirudin and its therapeutic aPTT range. Blood 96 : 846-851, 2000
PubMed
16) Warkentin TE, Elavathil LJ, Hayward CP et al : The pathogenesis of venous limb gangrene associated with heparin-induced thrombocytopenia. Ann Intern Med 127 : 804-812, 1997
PubMed
17) Arepally GM, Ortel TL : Heparin-induced thrombocytopenia. N Engl J Med 355 : 809-817, 2006
PubMed
18) Warkentin TE, Levine MN, Hirsh J et al : Heparininduced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin. N Engl J Med 332 : 1330-1335, 1995
PubMed
19) Magnani HN : Heparin-induced thrombocytopenia (HIT) : an overview of 230 patients treated with orgaran (Org10172) . Thromb Haemost 70 : 554-561, 1993
PubMed
20) Warkentin TE, Cook RJ, Marder VJ et al : Anti-platelet factor 4/heparin antibodies in orthopedic surgery patients receiving antithrombotic prophylaxis with fondaparinux or enoxaparin. Blood 106 : 3791-3796, 2005
PubMed
21) Savi P, Chong BH, Greinacher A et al : Effect of fondaparinux on platelet activation in the presence of heparin-dependent antibodies : ablinded comparative multicenter study with unfractionated heparin. Blood 105 : 139-144, 2005
PubMed
22) Kuo KH, Kovacs MJ : Fondaparinux : apotential new therapy for HIT. Hematology 10 : 271-275, 2005
 
23) Chong BH, Gallus AS, Cade JF et al : Prospective randomized operlabel comparison of danaparoid with dextran 70 in the treatment of heparin-induced thrombocytopenia with thrombosis : aclinical outcome study. Thromb Haemost 86 : 1170-1175, 2001
 
24) Farner B, Eichler P, Kroll H et al : Acomparison of danaparoid and lepirudin in heparin-induced thrombocytopenia. Thromb Haemost 85 : 950-957, 2001
 
25) Magnani HN, Gallus A : Heparin-induced thrombocytopenia (HIT) . A report of 1,478 clinical outcomes of patients treated with danaparoid (Orgaran) from 1982 to mid-2004. Thromb Haemost 95 : 967-981, 2006
PubMed
26) Matuo T, Tomaru T, Kario K et al : Incidence of heparin-PF4 complex antibody formation and heparininduced thrombocytopenia in acute coronary syndrome. Thromb Res 115 : 475-481, 2005
 
P.182 掲載の参考文献
1) Cohen AT, Davidson BL, Galleus AS et al : Efficacy and safety of fondaparinux for the prevention of venous thromboembolism in older acute medical patients : randomised placebo controlled trial. BMJ 332 : 325-329, 2006
 

Part7 各科領域におけるXa阻害薬の臨床応用の可能性をみる

P.189 掲載の参考文献
1) Sakuma M, Konno Y, Shirato K et al : Increasing morality form pulmonary embolism in Japan, 1951-2000. Circ J 66 : 1144-1149, 2002
 
2) Levine MN, Hirsh J, Gent M et al : Prevention of deep vein thrombosis after elective hip surgery. A randomized trial comparing low molecular weight heparin with standard unfractionated heparin. Ann Intern Med 114 : 545-551, 1991
PubMed
3) Warkentin TE, Greinacher A : Heparin-induced thrombocytopenia : recognition, treatment, and prevention. the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 126 : 311S-337S, 2004
PubMed
4) Geerts WH, Pineo GF, Heit JA et al : Prevention of venous thromboembolism. the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 126 : 338S-400S, 2004
PubMed
5) 黒岩政之, 古家仁, 瀬尾憲正ほか : 2004年周術期肺塞栓症発症調査結果からみた本邦における周術期肺血栓塞栓症発症頻度とその特徴. 麻酔55 : 1031-1038, 2006
 
6) 土井裕美, 保田知生, 小谷敦志ほか : 当科における術前深部静脈血栓症の術前術後管理. Ther Res 26 : 1156-1158, 2005
Medical*Online
7) Lopez Y, Parmo JA, Valenti JR et al : Hemostatic markers in surgery : adifferent fibrinolytic activity may be of pathophysiological significance in orthopedic versus abdominal surgery. Int J Clin Lab Res 27 : 233-237, 1997
 
8) Galster H, Kolb G Kohsytorz A et al : The pre-, peri-, and postsurgical activation of coagulation and the thromboembolic risk for different risk groups. Thromb Res 100 : 381-388, 2000
PubMed
9) Turpie AG, Bauer KA, Eriksson BI et al : Fondaparinux vs enoxaparin for the prevention of venous thromboembolism in major orthopedic surgery : a meta-analysis of 4 randomized double-blind studies. Arch Intern Med 162 : 1833-1840, 2002
PubMed
10) Agnelli G, Bergqvist D, Cohen AT et al ; PEGASUS investigators : Randomized clinical trial of postoperative fondaparinux versus perioperative dalteparin for prevention of venous thromboembolism in high-risk abdominal surgery. Br J Surg 92 : 1212-1220, 2005
PubMed
11) Bijsterveld NR, Moons AH, Boekholdt SM et al : Ability of recombinant factor VIIa to reverse the anticoagulant effect of the pentasaccharide fondaparinux in healthy volunteers. Circulation 106 : 2550-2554, 2002
PubMed
P.194 掲載の参考文献
1) Simoons ML, Bobbink IW, Boland J et al : Adose-finding study of fondaparinux in patients with non-ST-segment elevation acute coronary syndromes : the Pentasaccharide in Unstable Angina (PENTUA) Study. J Am Coll Cardiol 43 : 2183-2190, 2004
 
2) Mehta SR, Steg PG, Granger CB et al : Randomized, blinded trial comparing fondaparinux with unfractionated heparin in patients undergoing contemporary percutaneous coronary intervention : Arixtra Study in Percutaneous Coronary Intervention : a Randomized Evaluation (ASPIRE) Pilot Trial. Circulation 111 : 1390-1397, 2005
PubMed
3) Yusuf S, Mehta SR, Chrolavicius S et al : Comparison of fondaparinux and enoxaparin in acute coronary syndromes. N Engl J Med 354 : 1464-1476, 2006
PubMed
4) Yusuf S, Mehta SR, Chrolavicius S et al : Effects of fondaparinux on mortality and reinfarction in patients with acute ST-segment elevation myocardial infarction : the OASIS-6 randomized trial. JAMA 295 : 1519-1530, 2006
PubMed
5) Rao SV, Jollis JG, Harrington RA et al : Relationship of blood transfusion and clinical outcomes in patients with acute coronary syndromes. JAMA 292 : 1555-1562, 2004
PubMed
6) de Araujo Goncalves P, Ferreira J, Aquiar C et al : TIMI, PURSUIT, and GRACE risk scores : sustained prognostic value and interaction with revascularization in NSTE-ACS. Eur Heart J 26 : 865-872, 2005
 
7) Califf RM : Fondaparinux in ST-segment elevation myocardial infarction : the drug, the strategy, the environment, or all of the above? JAMA 295 : 1579-1580, 2006
PubMed
8) Alexander JH, Yang H, Becker RC et al : First experience with direct, selective factor Xa inhibition in patients with non-ST-elevation acute coronary syndromes : results of the XaNADU-ACS Trial. J Thromb Haemost 3 : 439-447, 2005
 
9) Gibbons RJ, Fuster V : Therapy for patients with acute coronary syndromes-new opportunities. N Engl J Med 354 : 1524-1527, 2006
PubMed
10) Antman EM, Morrow DA, McCabe CH et al : Enoxaparin versus unfractionated heparin with fibrinolysis for ST-elevation myocardial infarction. N Engl J Med 354 : 1477-1488, 2006
PubMed
11) Wallentin L, Goldstein P, Armstrong PW et al : Efficacy and safety of tenecteplase in combination with the low-molecular-weight heparin enoxaparin or unfractionated heparin in the prehospital setting : the Assessment of the Safety and Efficacy of a New Thrombolytic Regimen (ASSENT) -3 PLUS randomized trial in acute myocardial infarction. Circulation 108 : 135-142, 2003
 
P.200 掲載の参考文献
1) Geerts WH, Pineo GF, Heit JA et al : Prevention of venous thromboembolism : the seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 126 (3 suppl) : 338S-400S, 2004
 
2) 藤田悟 : 整形外科術後における静脈血栓塞栓症の頻度と予防. 静脈学15 : 295-301, 2004
 
3) 肺血栓塞栓症/深部静脈血栓症 (静脈血栓塞栓症) 予防ガイドライン作成委員会 : 整形外科手術. 肺血栓塞栓症/深部静脈血栓症 (静脈血栓塞栓症) 予防ガイドライン第1版, メディカルフロントインターナショナル, 東京, 2004, pp.55-64
 
4) Geerts WH, Heit JA, Clagett GP et al : Prevention of venous thromboembolism. Chest 119 (1 suppl) : 132S-175S, 2001
 
5) Herbert JM, Petitou M, Lormeau JC et al : SR 90107/Org 31540, a novel anti-factor Xa antithrombotic agent. Cardiovasc Drug Rev 15 : 1-26, 1997
 
6) Bauer KA, Eriksson BI, Lassen MR et al : Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after elective major knee surgery. N Engl J Med 345 : 1305-1310, 2001
PubMed
7) Eriksson BI, Bauer KA, Lassen MR et al : Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after hip-fracture surgery. N Engl J Med 345 : 1298-1304, 2001
PubMed
8) Turpie AG, Bauer KA, Eriksson BI et al : Postoperative fondaparinux versus postoperative enoxaparin of venous thromboembolism after elective hip-replacement surgery : arandomized double-blind trial. Lancet 359 : 1721-1726, 2002
 
9) Lassen MR, Bauer KA, Eriksson BI et al : Postoperative fondaparinux versus preoperative enoxaparin of venous thromboembolism in elective hip-replacement surgery : arandomized double-blind comparison. Lancet 359 : 1715-1720, 2002
 
10) Turpie AG, Gallus AS, Hoek JA : Asynthetic pentasaccharide for prevention of deep-vein thrombosis after total hip replacement. N Engl J Med 344 : 619-625, 2001
 
11) Turpie AG, Bauer KA, Eriksson BI et al : Fondaparinux vs enoxaparin for the prevention of venous thromboembolism in major orthopedic surgery : a meta-analysis of 4 randomized double-blind studies. Arch Intern Med 162 : 1833-1840, 2002
PubMed
12) Turpie AG, Bauer K, Eriksson B et al : Efficacy and safety of fondaparinux in major orthopedic surgery according to the timing of its first administration. Thromb Haemost 90 : 364-366, 2003
 
13) Eriksson BI, Lassen MR : Duration of prophylaxis against venous thromboembolism with fondaparinux after hip fracture surgery : amulticenter, randomized, placebo-controlled, double-blind stu dy. Arch Intern Med 163 : 1337-1342, 2003
 
14) Sullivan SD, Kwong L, Nutescu E : Cost-effectiveness of fondaparinux compared with enoxaparin as prophylaxis against venous thromboembolism in patients undergoing hip fracture surgery. Value Health 9 : 68-76, 2006
PubMed
15) Lundkvist J, Bergqvist D, Jonsson B : Cost-effectiveness of fondaparinux vs. enoxaparin as venous thromboembolism prophylaxis on Sweden. Eur J Health Econorn 4 : 254-262, 2003
PubMed
16) Colwell CW Jr, Kwong LM, Turpie AG et al : Flexibility in administration of fondaparinux for prevention of symptomatic venous thromboembolism in orthopaedic surgery. J Arthroplasty 21 : 36-45, 2006
PubMed
17) 冨士武史, 藤出悟 : 待機的股関節全置換術後の静脈血栓症の予防に対するFondaparinux Sodiumの有用性-プラセボを対照とした多施設共同無作為化二重盲検用量設定試験-. 日整会誌80 : S495, 2006
 
18) 冨士武史, 藤田悟 : 待機的膝関節全置換術後の静脈血栓症の予防に対するFondaparinux Sodiumの有用性プラセボを対照とした多施設共同無作為化二重盲検用量設定試験-. 日整会誌80 : S430, 2006
 

Part8 Xa阻害薬の安全性と副作用をみる

P.211 掲載の参考文献
1) Gruber A, Hanson SR : Factor XI-dependence of surface- and tissue factor-initiated thrombus propagation in primates. Blood 102 : 953-955, 2003
PubMed
2) Kleinschnitz C, Stoll G, Bendszus M et al : Targeting coagulation factor XII provides protection from pathological thrombosis in cerebral ischemia without interfering with hemostasis. J Exp Med 203 : 513-518, 2006
PubMed
3) Colman RW : Are hemostasis and thrombosis two sides of the same coin? J Exp Med 203 : 493-495, 2006
 
4) Herault JP, Bernat A, Pflieger AM et al : Comparative effects of two direct and indirect factor Xa inhibitors on free and clot-bound prothrombinase. JPharmacol Exp Ther 283 : 16-22, 1997
PubMed
5) Herbert JM, Petitou M, Lormeau JC et al : SR90107A/Org31540, a novel anti-factor Xa antithrombotic agent. Cardiovasc Drug Rev 15 : 1-26, 1997
 
6) Herault Jp, Bernat A, Pflieger AM et al : Comparative effects of two direct and indirect factor Xa inhibitors on free and clot-bound prothrombinase. J Pharmacol Exp Ther 283 : 16-22, 1997
PubMed
7) Turpie AG, Bauer KA, Eriksson BI et al : Fondaparinux vs enoxaparin for the prevention of venous thromboembolism in major orthopedic surgery : a meta-analysis of 4 randomized double-blind studies. Arch Intern Med 162 : 1833-1840, 2002
PubMed
8) Fifth Organization to Assess Strategies in Acute Ischemic Syndromes Investigators : Comparison of fondaparinux and enoxaparin in acute coronary syndromes. N Engl J Med 354 : 1464-1476, 2006
PubMed
9) Becker RC, Alexander J, Dyke CK et al : Development of DX-9065a, a novel direct factor Xa antagonist, in cardiovascular disease. Thromb Haemost 92 : 1182-1193, 2004
 
10) Alexander JH, Dyke CK, Yang H et al : Initial experience with factor-Xa inhibition in percutaneous coronary intervention : the XaNADU-PCI Pilot. J Thromb Haemost 2 : 234-241, 2004
 
11) Eriksson BI, Borris LC, Dahl OE et al : A once-daily, oral, direct Factor Xa inhibitor, rivaroxaban (BAY59-7939) . for thromboprophylaxis after total hip replacement. Circulation 114 : 2374-2381, 2006
 
12) Rebello SS, Bentley RG Morgan SR et al : Antithrombotic efficacy of a novel factor Xa inhibitor, FXV673, in a canine model artery thrombolysis. Br J Pharmacol 133 : 1190-1198, 2001
 
13) Eriksson BI, Turpie AG, Lassen MR et al : YMI50, an direct Factor Xa inhibitors, a prophylaxis for venous thromboembolism in patients with effective primary hip replacement surgery. A dose escalation study. Blood 106 : Abst. 1896, 2005
 
14) Rajagopal V, Bhatt L : Factor Xa inhibitors in acute coronary syndromes : moving from mythology to reality. J Thromb Haemost 3 : 436-438, 2005
 
15) Hull RD, Pineo GF, Stein PD et al : Timing of initial administration of low-molecular-weight heparin prophylaxis against deep vein thrombosis in patients following elective hip arthroplasty : asystematic review. Arch Intern Med 161 : 1952-1960, 2001
 
16) Strebel N, Prins M, Agnelli G et al : Preoperative or postoperative start of prophylaxis for venous thromboembolism with low-molecular-weight heparin in elective hip surgery? Arch Intern Med 162 : 1451-1456, 2002
PubMed
17) Turpie A, Bauer K, Eriksson B et al : Efficacy and safety of fondaparinux in major orthopedic surgery according to the timing of its first administration. Thromb Haemost 90 : 364-366, 2003
 
18) 冨士武史, 藤田悟 : 待機的股関節全置換術後の静脈血栓症の予防に対するFondaparinux Sodiumの有効性-プラセボを対照とした多施設共同無作為化二重盲検用量設定試験-. 日整会誌80 : S495, 2006
 
19) 冨士武史, 藤田悟 : 待機的膝関節全置換術後の静脈血栓症の予防に対するFondaparinux Sodiumの有効性-プラセボを対照とした多施設共同無作為化二重盲検用量設定試験-. 日整会誌80 : S430, 2006
 

Part9 Xa阻害薬の将来展望を探る

P.218 掲載の参考文献
1) Sullivan SD, Davidson BL Kahn SR et al : A costeffectiveness analysis of fondaparinux sodium compared with enoxaparin sodium as prophylaxis against venous thromboembolism : use in patients undergoing major orthopaedic surgery. Pharmacoeconomics 22 : 605-620, 2004
PubMed
2) Sullivan SD, Kwong L, Nutescu E : Cost-effectiveness of fondaparinux compared with enoxaparin as prophylaxis against venous thromboembolism in patients undergoing hip fracture surgery. Value Health 9 : 68-76, 2006
PubMed
3) Dranitsaris G, Kahn SR, Stumpo C et al : Pharmacoeconomic analysis of fondaparinux versus enoxaparin for the prevention of thromboembolic events in orthopedic surgery patients. Am J Cardiovasc Drugs 4 : 325-333, 2004
PubMed
4) Gordois A, Posnett J, Borris L et al : The cost-effectiveness of fondaparinux compared with enoxaparin as prophylaxis against thromboembolism following major orthopedic surgery. J Thromb Haemost 1 : 2167-2174, 2003
PubMed
5) Bjorvatn A, Kristiansen F : Fondaparinux sodium compared with enoxaparin sodium : acost-effectiveness analysis. Am J Cardiovasc Drugs 5 : 121-130, 2005
 
6) Annemans L, Minjoulat-Rey MC, De Knock M et al : Cost consequence analysis of fondaparinux versus enoxaparin in the prevention of venous thromboembolism after major orthopaedic surgery in Belgium. Acta Clin Belg 59 : 346-357, 2004
PubMed
7) 藤田悟, 冨士武史, 三井忠夫ほか : 股関節または膝関節全置換術後における深部静脈血栓症および肺塞栓症の発生頻度-予見的多施設共同研究-. 整形外科51 : 745-749, 2000
 
8) 冨士武史, 中村真潮, 山田典一ほか : 深部静脈血栓症予防の医療経済分析 薬剤経済分析 (phamlacoeconomics) の応用. 綜合臨床54 : 2988-2997, 2005
 
9) Oster G, Tuden RL, Colditz GA : Acost-effectiveness analysis of prophylaxis against deep-vein thrombosis in major orthopedic surgery. JAMA 257 : 203-208, 1987
 
P.227 掲載の参考文献
1) Huntington JA : Molecular recognition mechanism of thrombin. J Thromb Haemost 3 : 1861-1872, 2005
PubMed
2) Francischetti IM, Valenzuela JG, Anderson JF et al : Ixolaris, a novel recombinant tissue factor pathway inhibitor from the salivary gland of the tick, Ixodes scapularis : identification of factor X and factor Xa as scaffolds for the inhibition of factor VIIa/tissue factor complex. Blood 99 : 3602-3612, 2002
 
3) Waxman L, Smith DE, Arcuri KE et al : Tick anticoagulant peptide (TAP) is a novel inhibitor of blood coagulation factor Xa. Science 248 : 593-596, 1990
PubMed
4) van de Locht A, Stubbs MT, Bode W et al : The ornithodorin-thrombin crystal structure, a key to the TAP enigma? EMBO J 15 : 6011-6017, 1996
 
5) Chopin V, Salzet M, Baert JI et al : Therostasin, a novel clotting factor Xa inhibitor from the rhynchobdellid leech, Theromyzon tessulatum. J Biol Chem 275 : 32701-32707, 2000
 
6) Di Nisio M, Middeldorp S, Buller HR : Direct thrombin inhibitor. N Engl J Med 353 : 1028-1040, 2005
PubMed
7) Mann KG : Biochemistry and physiology of blood coagulation. Thromb Haemost 82 : 165-174, 1999
PubMed
8) Boneu B, Necciari J, Cariou R et al : Pharmacokinetics and tolerance of the natural pentasaccharide with high affinity to antithrombin III in man. Thromb Haemost 74 : 1468-1473, 1995
PubMed
9) Lagrange F, Vergnes C, Brun JL et al : Absence of placental transfer of pentasaccharide (Fondaparinux, Arixtra) in the dually perfused human cotyledon in vitro. Thromb Haemost 87 : 831-835, 2002
PubMed
10) Dempfle CH : Minor transplacental passage of fondaparinux in vivo. N Engl J Med 350 : 1914-1915, 2004
PubMed
11) Eriksson BI, Lassen MR ; PENTasaccharide in Hip FRActure Surgery Plus Investigators : Duration of prophylaxis against venous thromboembolism with fondaparinux after hip fracture surgery : amulticenter, randomized, placebo-controlled double-blind study. Arch Intern Med 163 : 1337-1342, 2003
 
12) Cohen AT, Gallus AS, Lassen MR et al : Fondaparinux vs. placebo for the prevention of vcnous thromboembolism in acutely ill medical patients. J Thomb Haemost 1 (suppl 1) : 2046, 2001
 
13) Agnelli G, Bergqvist D, Cohen A : Arandomized double-blind study to compare the efficacy and safety of fondaparinux with dalteparin in the prevention of venous thromboembolism after high-risk abdominal surgery : The Pegasus Study. J Thromb Haemost 1 (suppl 1) : OC006, 2003
 
14) Buller HR, Davidson HR, Decousus H et al : Fondaparinux or enoxaparin for the initial treatment of symptomatic deep venous thrombosis : arandomized trial. Ann Intern Med 140 : 867-873, 2004
 
15) Buller HR, Davidson BL, Decousus H et al ; Matisse Investigators : Subcutaneous fondaparinux versus intravenous unfractionated heparin in the initial treatment of pulmonary embolism. N Engl J Med 349 : 1695-1702, 2003
PubMed
16) Coussement PK, Bassand JP, Convens C et al : A synthetic factor-Xa inhibitor (ORG31540/SR9017A) as an adjunct to fibrinolysis in acute myocardial infarction. The PENTALYSE study. Eur Heart J 22 : 1716-1724, 2001
PubMed
17) Fergusson JJ : Meeting highlights-American Heart Association scientific sessions 2001. Circulation 105 : e37-e41, 2002
 
18) Yusuf S, Mehta SR, Chrolavicius S et al ; The Fifth Organization to Assess Strategies in Acute Ischemic Syndromes Investigators : Comparison of fondaparinux and enoxaparin in acute coronary syndromes. N Engl J Med 354 : 1464-1476, 2006
PubMed
19) Herbert JM, Herault Jp, Bernat A et al : Biochemical and pharmacological properties of SANORG 34006, a potent and long-acting synthetic pentasaccharide. Blood 91 : 4197-4205, 1998
PubMed
20) Lassen MR, Davidson BL, Gallus A et al : Aphase II randomized, double-blind, five-arm parallel-group, dose-response study of a new oral directly-acting factor Xa inhibitor, razaxaban for the prevention of deep vein thrombosis in knee replacement surgery. Blood 102 : 41, 2003
 
21) Schulman S, Wahlander K, Lundstrom T et al : Secondary prevention of venous thromboembolism with the oral direct thrombin inhibitor ximelagatran. N Engl J Med 349 : 1713-1721, 2003
PubMed
22) Turpie AG, Bauer KA, Eriksson BI et al : Fondaparinux vs enoxaparin for the prevention of venous thromboembolism in major orthopedic surgery : a meta-analysis of 4 randomized double-blind studies. Arch Intern Med 162 : 1833-1840, 2002
PubMed
23) Coughlin SR : Protease-activated receptors in hemostasis, thrombosis, and vascular biology. J Thromb Haemost 3 : 1800-1814, 2005
PubMed
24) Vergnolle N, Bunnett NW, Sharkey KA et al : Protease-activated receptor-2 and hyperalgesia. A novel pain pathway. Nat Med 7 : 821-826, 2001
PubMed
25) Hjortoe GM, Petersen LC, Albrektsen T et al : Tissue factor-factor VIIa-specific up-regulation of IL-8 expression in MDA-MB-231 cells is mediated by PAR-2 and results in increased cell-migration. Blood 103 : 3029-3037, 2004
PubMed
26) Camerer E, Kataoka H, Kahn M et al : Genetic evidence that protease-activated receptors mediate factor Xa signaling in endothelial cells. J Biol Chem 277 : 16081-16087, 2002
PubMed

書評

最近チェックした商品履歴

Loading...